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ABSTRACT
The development of fluorogenic substrates for real- time tumor cell detection has led to a
vastly expanding field for personal oncology. Fluorophores have been studied as appendages to
larger scaffolds leading to accumulation of these dyes in tumor cells or their surrounding
environment, taking advantage of tumor anatomy.

A new class of fluorophores has been

developed in which the dye is an active participant in the mechanism of cancer cell detection.
These dyes have been conjugated such that their fluorescence has been eliminated or altered and
will undergo a change to reveal their fluorescent signal upon activation by a mechanism that is
unique to tumor cells.
The research presented in this dissertation encompasses the design, synthesis, properties,
and utilization of latent fluorophores that are specifically activated by an enzyme that is
highly upregulated in tumor cells, NAD(P)H:quinone oxidoreductase-1 (NQO1). These dyes
utilize the 2-electron reduction of quinones to hydroquinones, which NQO1 specifically
catalyzes. A dye’s fluorescence can be quenched by conjugating a quinone directly to the
fluorophore, only to have its signal uncloaked after activation by NQO1. The objectives in this
research will be achieved by: (1) the characterization of properties (stability in biological
environments, quantum yields) of the quinone, dyes, and their conjugated counterparts; (2)
determination of kinetic parameters (Michaelis constant (K m ), theoretical maximum velocity

xvii

(V max ), catalytic constant (k cat ), enzyme efficiency (k cat /Km ) of the substrates towards NQO1 and
the way solvent affects such parameters during assay conditions; and (3) utilization of a latent
fluorophore for in vivo NQO1 analysis (widefield imaging, confocal single-/two-photon
microscopy, flow cytometry) and determining the fate of the released fluorophore. Integration of
these studies led to the development of two different latent fluorophores that are readily activated
by NQO1. Of these two fluorogenic cancer sensors, one was found to possess a highly novel
quenching mechanism between the quinone and the dye.

xviii

CHAPTER 1
INTRODUCTION
1.1

Research Goals and Aims
The goal of this research is the design and characterization of latent fluorophores used as

sensors for the detection of NAD(P)H:quinone oxidoreductase-1 (NQO1) in tumor cells.1-4

In

particular, the design of the fluorogenic sensor is such that it will need to contain a cleavable
substrate that is selectively activated by NQO1 and a fluorophore that will have its fluorescence
quenched when conjugated with said substrate. Both the quenched dye and the free dye will be
tested to ensure high stability while in a biological milieu. Both the capped dye and free dye had
their optical properties examined to ensure a high probability of success in their application as an
“off-on” type sensor.

These fluorogenic sensors will be tested in vitro with cancer cell lines

known to contain NQO1 and cells known to be devoid of the enzyme.
Sir George Gabriel Stokes first observed fluorescence in the early 19th century and coined
the term “fluorescence” after noticing a blue light emitting from a solution of quinine sulfate.
Since then, fluorescent dyes have made an immense impact in biological sciences, and more
recently in the field of biomedical imaging.5-6

Biomedical imaging has become a crux in the

field of screening and disease treatment of cancer patients.7

Statistics such as 1,638,910 new

cancer cases and 577,190 deaths projected in the year 2012 provide motivation for the need of
better detection and treatment of such a widespread disease.8

Biomedical imaging has been at

the heart of the cancer treatment by assisting with prediction, screening, biopsy guidance for
detection, staging, prognosis, therapy planning, therapy guidance, therapy response, recurrence,
and palliation.9

Techniques involved in cancer detection and diagnosis are: magnetic resonance

imaging (MRI), positron emission tomography (PET), X-ray, radiography, ultrasound, and
nuclear medicine.

But, these techniques lack specificity, sensitivity, and may yield radioactive
1

risks.9

With a better understanding of the processes in the human body and the

anatomy/biochemistry of tumors, better optical imaging agents and techniques have emerged.
This type of imaging has been promising because it is non-invasive, potentially provides realtime information, and can provide high spatial resolution of cancerous tissues.10
Though the research into fluorophores relevant to cancer diagnosis/treatment has been
expanding rapidly, there are currently only three clinically-approved exogenous fluorescent
tracers.11

Fluorescent sensors can be broken down into two categories: always on and off-on.

These can be classified into two subcategories of organic and inorganic fluorophores.10 Alwayson fluorophores are typically conjugated to larger scaffolds such as macromolecules, peptide
sequences, and antibodies, and they have been utilized for tumor imaging through a receptormediated process or accumulation from enhanced permeability and retention (EPR) within
tumors.12

The drawback to this process is long accumulation time within the body, leading to

poor contrast when imaging.13 Off-on type activatable sensors have been shown to be superior to
always-on fluorophores due to the low background signal produced in the quenched state and the
large

fluorescence

fluorophore.14

enhancement

(FE)

after

activation and

subsequent

release

of the

Even with the fact that NQO1 is a highly upregulated enzyme in cancer cells that

selectively reduces quinoid compounds via a 2-electron reduction, no dyes have been reported
for use in real-time in vitro sensors of this enzyme.15
O
O

2H/2eO

O

O

Dye

Trimethyl- lock

OH

Dye

Lactonization

O

+ Dye
OH

OH

Scheme 1.1. Illustration of the NQO1-activatable substrate and dye release mechanism.

2

The first aim of this research is the development of two NQO1-activatable fluorescent
sensors to be used as intracellular probes. The base of these dyes will be the activatable quinone
substrate that is selectively activated by NQO1.

The quinone unit will contain a trimethyl-lock

(Q 3 ) motif, which has been shown to substantially increase the rate of cyclization and
subsequently should lead to a rapid dye release.16

The first fluorophore synthesized will contain

a rhodamine-morpholino urea dye conjugated to Q 3 .

This rhodamine-based dye has been

previously shown to have a high intensity in the mono-conjugated form and be nearly completely
quenched when di-conjugated.17-19

The second dye will pair a naphthalimide dye with the Q 3

moiety via a short spacer. This “fluorophore-spacer-receptor” dye has its fluorescence quenched
as a result of a novel use of photoinduced electron transfer (PeT).20

After each dye was

synthesized, they were tested to ensure rapid release of the attached dye subsequent to quinone
reduction.

To this end, the quinone units were chemically reduced with a strong reducing agent

(sodium dithionite, Na 2 S 2 O 4 ), and the fluorescence intensity was followed over time.

To

confirm the quinone activating group was highly stable and could withstand the known reducing
intracellular environment,

the Q 3

capped rhodamine dye was investigated while under

physiological conditions in the presence of biological reductants.

This fluorophore was

incubated with NADH (E 1/2 = -0.31 V)21 , ascorbic acid (E 1/2 = 0.051 vs. SHE)22 , glutathione
(E 1/2 = -0.22 V)23 , and dithiothreitol (E 1/2 = -0.33 V)24 , and the fluorescence signal was observed
in order to determine if release was taking place.

To confirm the capability of the Q 3 -capped

naphthalimide dye to be quenched via PeT, the reduction/oxidation potentials of the quinone unit
and the naphthalimide dye were determined using cyclic voltammetry (CV), and they were used
to calculate the energy change (∆G)25 from the Rehm-Weller equation.

3

The second aim of this work is characterization of the optical properties of the
fluorophores and determination of the effectiveness at which NQO1 activated the sensors by
performing enzyme kinetics.

To determine the FE from pre- and post-activation of the dyes, a

quantum yield for each dye was determined. To determine the quantum yield for the capped and
free dyes, the fluorescence signal was compared to a compound with a well-known quantum
yield; for the rhodamine-based dyes, fluorescein was used, while quinine sulfate was compared
to the naphthalimide dyes.17,

26

Enzyme assays and the kinetic parameters they yield provide

information for how effective the sensors are as substrates for NQO1 and can be related to other
published compounds.

By assaying the capped sensors with human NQO1 (hNQO1), kinetic

parameters of K m (Michaelis constant, substrate affinity), V max (maximum theoretical turnover
rate), k cat (catalytic constant), and k cat /K m (enzyme efficiency) were produced.
The final aim of this research is determination of the applicability of the fluorophores as
in vivo sensors of hNQO1.

To complete this objective, multiple cell lines of different origins

that are known to contain or be devoid of hNQO1, were purchased and incubated with the dyes
and subsequently analyzed using: fluorescence plate reader, flow cytometry, and fluorescence
imaging using a widefield microscope and single-/two-photon microscope.

From these analyses,

it is possible to determine if each sensor was selectively activated in the cell lines known to
contain hNQO1 or remain inactivate in the cell lines devoid of the enzyme.

If the sensor was

found to be activated, its fate was determined post-activation using colocalization experiments
(confocal microscopy).
From the information presented in this work, I have demonstrated a novel use of NQO1
as a rapid in vivo sensor in tumor cells. The results presented in this work lay the groundwork
for the next steps in NQO1 sensor utilization, possibly leading to ex vivo and in vivo analysis of

4

tumors.

Illustrated is a first-generation sensor which has great potential to lead to further

advancements in creating fluorophores for the detection of NQO1.

Also, there is potential to

create a better understanding of the role NQO1 plays in tumors and possibly in cancer analysis
and treatment.
1.2

Biomedical Optical Imaging
Biomedical optical imaging has rapidly emerged as a field with the potential to impact all

areas of cancer research and personal oncology, from the molecular level to a living system, and
from the bench to the bedside.

In the clinic, biomedical imaging plays a major role in all facets

of cancer management by non-invasively detecting and visualizing biological processes within a
living system.27 These major involvements include: prediction,28 screening,29-30 biopsy guidance
for detection,31 staging,32-34 prognosis,35 therapy planning,36-37 therapy guidance,38 therapy
response,39-42 recurrence,43 and palliation.9

On the research (preclinical) side, imaging assists in

the fundamental understanding of molecular pathways involved in carcinogenesis, aids in drug
discovery, and provides a better understanding of the morphologic and biochemical processes
within individual cells, tumors, and whole organs.27

The instrumentation predominantly used in

cancer management include: magnetic resonance imaging (MRI), positron emission tomography
(PET), computerized tomography (CT), X-ray, radiography, and ultrasound.

Though these

methodologies are common place in the clinic, they lack specificity, sensitivity (Figure 1.1), and
may yield radiation.10

The only clinically used techniques with sufficient sensitivity for

molecular imaging are nuclear imaging techniques.

However, nuclear imaging techniques have

severe drawbacks, such as: a cyclotron is used to develop radiotracers, radioactivity handling,
lack of shelf life for the radiotracers, and the need to balance the half-life of the radiotracer with
the pharmacokinetics of the targeting agent.44

Also, the majority of the biomedical imaging
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techniques are impractical in the research lab due to cost and spatial resolution when compared
to optical imaging techniques.27

Figure 1.1 Relative sensitivity of imaging technologies; from Fass (2008).
Optical imaging in both clinical and preclinical applications has been expanding due to
the low cost, real-time analysis, non-invasiveness, ability to image at microscopic and
macroscopic level (subcellular to whole animal body to human organ), specificity of probes, and
sensitivity.

Optical imaging in cancer diagnostics originally observed changes in the contrast of

endogenous sources.

Due to neoplastic tissues forming from cancer, biochemical and

morphological alterations could be observed by changes in absorbance, light scattering,
fluorescence, and polarization properties.27

One such characteristic change is a decrease in the

fluorescence in the green region from stromal collagen cross-links as they are broken down from
carcinogenesis.45

Similarly, an increase in fluorescence from nicotinamide adenine dinucleotide

(NADH) and flavin adenine dinucleotide (FAD) have been attributed to an increase in metabolic
activity.46

One of the benefits of imaging endogenous sources is there is no need for

administering exogenous agents that require approval for clinical use. However, these sources of
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optical contrast are rarely limited to only carcinogenesis.27

Currently, the most common

approach to increasing contrast and sensitivity in optical imaging is the use of exogenously
introduced fluorophores.

These can be used as individual species or conjugated to larger

scaffolds; examples are shown in Figure 1.2.

Figure 1.2. Five classes of molecularly-specific optical contrast agents. From left to right in
order of increasing size: small molecules including glucose and peptides can be functionalized
with fluorescent dyes. Aptamers can be designed to form activatable ‘‘smart probes,’’ with
fluorescence quenched until target binding. Antibody probes are generally functionalized with
fluorescent dyes in the Fc domain. Targeting molecules can be coupled to nanoparticle-based
optical reporters, including gold nanoparticles and quantum dots; from Pierce et al. (2008).
Each of the fluorophore categories in Figure 1.2 can be utilized in a variety of techniques,
from preferential accumulation in tumor sites47-48 to specifically targeting of endogenous
ligands49 .

Other such non-specific fluorophores have been used to increase contrast in optical

imaging,50-52 while new off-on sensors are being studied to switch from a nonfluorescent state to
a fluorescent state in the presence of a specific biochemical event.12 The existence of all imaging
probes and fluorophore-scaffolds is to provide high sensitivity and specific interactions with the
biological targets, though the path to that goal may vary.
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Optimal imaging fluorophores must

possess large Stokes shift for minimum interference between absorption and emission, high
molar extinction coefficient, high quantum yield, photo-stability, biological stability, and water
solubility with minimal aggregation.10

Depending on the imaging application,

specific

wavelengths may prove to be more valuable to provide the essential signal-to-background ratio
(SBR). With in vitro and ex vivo optical imaging, a wider spectrum of wavelengths may be used
due to less endogenous interference. With in vivo and clinical applications, it is of great value to
develop probes in the near-infrared (NIR) region (650 to 900 nm). This is due to the scattering
and absorbance of light in tissue components, oxy-/deoxyhemoglobin, and water, Figure 1.3.53

Figure 1.3.
Extinction coefficient value of water, oxy- and deoxyhemoglobin are plotted
ranging from visible to near-infrared wavelength; from Kobayashi et al. (2010).53
1.2.1

Instrumentation
The instrumentation used for optical imaging can vary greatly, depending on the

application and biochemical or physiological process being observed.

Benchtop (research lab)-

based imaging can require subcellular resolution to obtain information on intra-/extracellular
biochemical and biophysical processes,54 and up to macroscopic resolution to observe
8

physiological events in whole animals.55

Optical imaging in the clinical aspect ranges from

cellular resolution for surgical guidance in resecting tumors56 to whole organ imaging for cancer
diagnosis.57-58

Outside

of image-guided

invasive

biopsy,

current

biomedical imaging

technologies are not performed at the same time as the treatment. The use of fluorescence-based
optical modalities offers the opportunity for both real-time in situ diagnosis and treatment at the
same time as surgical procedures.44

Detailed below is a non-exhaustive list of common

techniques, descriptions, and current work utilizing preclinical and clinical modalities for the
optical imaging of exogenously introduced fluorophores.
Confocal microscopy has become a common imaging technology in the laboratory due to
its high contrast and high resolution (between 0.21 to 0.58 µm spatially and 0.44 to 3.44 µm
axially)59 of thin samples, such as cells and tissue.

The primary characteristic of the confocal

microscope is the use of continuous wave lasers to excite samples and use a pinhole aperture to
remove out-of-focus light from non-observed emitting samples.

Images are built point-by-point

as the imaging laser scans a sample, leading to the ability to produce high quality 2D and 3D
images.27

This type of imaging is ideal for preclinical in vitro analysis, because it is non-

destructive and has the ability to image cellular samples in their physiological state.

In vitro

imaging is also a more controlled environment than in vivo analysis, providing a better
determination of the future efficacy of the compound under study.

With confocal microscopy,

protein interaction can be observed60 and the fate of exogenous agents can be determined after
compartmentalization and intracellular trafficking by using multiple contrast agents in a single
sample.61

By obtaining a better understanding of the intra/extracellular biochemical components

and processes of cancerous cells, it is possible to gain better insight into the processes of the
formation of neoplastic tissue during carcinogenesis.
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The intracellular fate of drugs, drug

delivery systems, and imaging agents yields crucial information in providing insight into future
efficacy, such as in vivo analysis, and aids in future development of new drugs and imaging
systems.

Confocal imaging is also a rapid analysis technique when evaluating active targeting

fluorogenic probes against specific cellular epitopes.62

With the constant miniaturization of

imaging technology, new methodologies are being developed from older instrumentation.

Work

has been done to create a portable endoscopic confocal imaging device that utilizes multiple
flexible/narrow-diameter fiber optic cables, miniature lenses, and compact scanning mechanisms,
Figure 1.4.63-64

This imaging platform has been able to achieve a lateral resolution of 2.0 µm

and an axial resolution of 25 µm;65 it has also been used in clinical studies to image the
gastrointestinal tract,64 colon,66 and ovaries.65
Spectroscopy
Channel
Imaging Channel
(Photodetector)

Miniprobe
(Fiber-optic bundle)

Miniprobe
(Fiber-optic bundle)

Laser Scanning Unit

(LSU)

Figure 1.4. Schematic diagram of the prototype F400/S (Mauna Kea Technologies), a dual
fibered confocal imaging and spectroscopic platform; from Thiberville (2007).64

As a result of the need for deeper tissue penetration and the existence of the highly
successful confocal microscope, multiphoton microscopy was developed.
10

This technique

exploits the high-resolution capabilities of the confocal microscope, but uses a pulsed laser with
longer wavelength excitation.

This longer wavelength generates less Rayleigh scattering and

allows for deeper sample penetration for optical imaging.

In this method, fluorophores are

excited by near-simultaneous absorption of 2 (or more) photons at half the energy of the singlephoton transition, Figure 1.5.

This is possible by rapidly pulsing (~100 fs pulse width, 80 MHz

pulse frequency) the sample with the laser beam.27 Whereas continuous wave lasers in confocal
microscopy excite all fluorophores in the path of the laser beam, pulsed lasers only generate
sufficiently excited molecules (to generate fluorescence) at the focal point, Figure 1.5.67

This

modality has not only provided superb in vitro analysis of carcinogenesis.27

A

B

Figure 1.5. Continuous-wave vs. pulsed laser: a continuous-wave laser can be thought to consist
of a steady stream of photons. A pulsed laser beam can be thought to be composed of a stream of
evenly spaced, tightly grouped photon packets (A). Jablonski diagrams for confocal (onephoton) and two-photon fluorescence interactions (B); from Christensen and Nedergaard
(2011).67
Brown et al. have shown that multiphoton microscopy used for in vivo imaging of tumor
models in live mice can provide insight into tumor physiology by measuring gene expression,
angiogenesis,
tumors.68

blood-flow

velocities,

leukocyte/endothelial interactions,

and

permeability of

Runnels et al. were able to fluorescently label vascular endothelial cell adhesion

molecules so as to obtain spatial and temporal relationships and build 3D images of the
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vasculature, while also following specific populations of cells.69

This use of live animals for

multiphoton imaging leads to the possibility of studying inflammation, angiogenesis, and
atherogenesis.69

While multiphoton microscopy has become vital in the imaging of in vitro and

in vivo settings and has provided unprecedented insights into the process of carcinogenesis, the
ability to miniaturize the methodology has been hampered due to the translation of the pulse
laser to utilize fiber-optic cables.27

Though the miniaturization has been slower compared to

confocal microscopy, there have been recent reports of imaging endoscope systems utilizing
multiphoton microscopy.70-72
Though the goal for optical imaging modalities remains to be real-time analysis of
the area under investigation, many real-time optical imaging instruments for clinical use have
emerged since the first clinical applications of fluorescently guided surgery using indocyanine
green (ICG) to aid in the resection of the sentinel lymph node.56,

73-77

The basic setup for each

imaging system includes light emitting diodes (LEDs) or lasers that emit a narrow bandwidth,
band-pass filters to limit possible detection of the excitation source, and a charge-coupled device
(CCD) camera for the collection of the emission signal.11

One of the first clinically used

fluorescence-guided optical imagers was the fluorescence-assisted resection and exploration
(FLARE) system, which was designed and used by the Frangioni research group.75

This

widefield imaging device is capable of exciting fluorophores at 656 — 678 nm and 745 — 779
nm, and it contains a CCD camera with band-pass filters at 689 to 725 nm and 800 to 848 nm.11
It possesses a field of view (FOV) between 3.7 to 195 cm2 , and uses more than one imaging
camera to allow for image overlay between visual and fluorescence images. Since the inception
of the FLARE imaging device, Frangioni has developed a second-generation machine called the
mini-FLARE, Figure 1.6.78

This imaging device contains the same imaging parameters as
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FLARE, with updated technology and a shorter working distance: 45 cm for flare and 10 to 32
cm for mini-FLARE.11

A

B

C

Figure 1.6. The Mini-FLARE portable near-infrared fluorescence imaging system, composed of
electronics/monitor cart and counterweighted imaging system pole (A). Sterile drape/shield
attached to the imaging head (B). The portable/hand-held Photodynamic Eye (C); from Mieog et
al. (2011) and Tagaya et al. (2008).74, 78
As technology progresses, there is a desire to utilize the ever decreasing size of
electronics and optics in newer imaging systems.

The Photodynamic Eye (PDE, Photonics,

Hamamatsu, Japan) is a commercially-available system that is a more portable optical imaging
system compared to the (mini-)Flare system, Figure 1.6. With the reduction in size, it has fewer
capabilities than other systems.

The PDE only provides black and white images of the area of

interest, and only excites at 760 nm with 36 LEDs.79 Another advantage of this reduction in size
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is the ability to produce laparoscopic imaging systems for minimally invasive surgery.

To date,

there are only four clinically-approved systems: the D-light80 and D-light NIR81 systems,
Olympus narrow-band imaging (NIB),82 and an integrated system52 for the da Vinci Si Surgical
robot.11
1.2.2

Nanomaterial-Based Sensors
Of all the in vivo imaging probe types, nanomaterials have certainly been one of the more

intriguing.

The most beneficial aspects of nanomaterial-based probes are their photostability,

brightness, narrow excitation/emission bands, utilization of the EPR effect to allow for
their passive accumulation in tumor sites, and ability to functionalize the exteriors as to allow
for their association with different functionalities.83

However, the major drawbacks in the use

of these sensors in the clinic are concerns about their toxicity,84-85 poor biodistribution due
to uptake by the reticuloendothelial system (RES), only having a 2:1 to 4:1 signal-to-background
ratio with passive uptake probes, and the inability to passively accumulate intracellularly (though
this can be achieved through mediated endocytosis) due to the size of the particles.

The

two main types of nanoprobes are organic-based nanoparticles (polymer-core nanoparticle,
polymer micelles, polymersomes, liposomes, lipid micelles, and lipid-core nanoparticles) and
inorganic nanocrystals (semi-conducting quantum dots (QD) and silica nanoparticles), Figure
1.7.83

Due to their intense fluorescent signal, ability to shift excitation/emission wavelengths

by adjusting particle size, and photostability, QDs have emerged as useful tools in the optical
imaging field and have led to a plethora of commercially-available dyes.

The most common

QDs are ZnS, CdSe, and CdTe, and typically have their surface coated with organic material (i.e.
poly(ethylene glycol) (PEG)) to prolong blood lifetime between 48 and 72 hours and prevent
protein adsorption.83,

86

The size of the nanoparticles has been found to have a profound effect
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on the ability to accumulate in tumor sites in in vivo experiments. Nanoparticles in the range of
111 to 141 nm were found to accumulate efficiently, while particles larger than 166 nm were
rapidly removed by the RES.87

A
B

C

D

F

E

I

H

J

G

K

Figure 1.7. Inorganic nanoprobes are quantum dots (A) or dye-loaded silica, calcium phosphate,
gold or oxide nanoparticles, for which the organic dye can be included in the inorganic matrix
(B), or grafted on the nanoparticle surface (C). Organic nanoprobes can be divided in two main
families: dye-loaded polymer-based and dye-loaded lipid-based nanoparticles. In each family,
different architectures can be found: polymer- or lipid- core particles (polymer nanospheres (D),
proteins (E), lipid nanoparticles (F), lipoproteins (G)), self-assembled constructions (polymer
(H) or lipid (I) micelles), nanocapsules (polymersomes (J) or liposomes (K)). The fluorescent
organic dye can be either included in the hydrophobic core or shell of the structure, or grafted on
the nanoparticle surface (hydrophilic organic dye). From Merian et al (2012).83
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One of the first in vivo imaging experiments was performed by Gao et al., where they
successfully synthesized a tri-block polymer-coated CdSe QD with prostate-specific membrane
antigens (PSMA) attached.

This attachment of PSMA to the outer shell of the nanoparticle

allowed the QDs to effectively adhere to prostate tumor cells in mice (from a xenograft),
allowing for sensitive and specific in vivo imaging.86

Cai et al. similarly produced a polymer-

coated QD using arginine-glycine-aspartic acid as the targeting ligand, which binds to the α v β 3
integrin that is known to play a role in angiogenesis and metastasis.88

This imaging probe

produced maximum intensity after 6 hours post-injection, with good contrast in a mouse model.
Organic-based nanocarriers have been studied extensively over the last several decades as
drug delivery systems, with several clinically-approved applications.83,

89-90

Because of this,

these nanocarrier systems have been studied extensively, and their in vivo fate and
biodistribution have been determined.

Similar to QDs, organic-based nanocarriers are typically

conjugated to PEG to minimize removal by the RES and to extend blood circulation time.
Tumor targeting ligands—such as antibodies, peptides, and saccharides—have also been
attached so as to increase targeting efficacy.83

The use of organic-based nanocarriers has only

recently been studied as a vehicle for in vivo fluorescent probes.

One of the main systems

studied is the dye-loaded lipid based liposome, due to the vast amount of previous work using
liposomes as drug delivery systems.

Here, liposomes encapsulate fluorophores and will

accumulate in tumor sites in vivo due to the EPR effect.

Sandanaraj et al. demonstrated

the

and

use

of

an

egg

phosphaditylcholine,

phosphoethanolamine-N-methoxy-(poly(ethylene

cholesterol,

glycol)2000)-based

1,2-disteroyl-sn-glycero-3liposome

that

contains

cyanine 5.5 (Cy5.5) and indocyanine green (ICG) as an in vivo probe for tumors and arthritis
disease models in mice.91 This system was observed to be highly stable for up to 70 days, and it
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was found to passively accumulate in tumor sites due to the EPR effect.

Portnoy et al.

synthesized liposomes from phospholipon 50 and noncovalently-attached ICG, and monoclonal
antibodies for epidermal growth factor receptor (EGFR) to them.92
ligand that has been found to be overexpressed in carcinomas.

EGFR is an extracellular

This dye system was optically

imaged in vitro and was found to selectively bind to membrane bound receptors, which led to
endocytosis.
1.2.3

Antibody-Based Sensors
Another option to increase contrast for intraoperative tumor analysis (in vivo and in vitro

imaging) is the direct conjugation of always-on fluorophores to antibodies with known
associations

pertaining to

specific cell types.

This process is commonly used

immunohistochemical labeling of fixed cells and cell assays.

for

Some of the drawbacks to this

method are the possibility of loss of antibody recognition after dye conjugation, loss of
fluorescence signal after conjugation, limited availability of antibodies, localization of epitopes,
and the need to maintain proper controlled environmental conditions that prevent antibody
degradation.10,

27

As with always-on nanoprobes, antibody-based imaging constructs require

sufficient clearance time in vivo to obtain an optimal SBR when imaging.

Soukos et al.

produced a monoclonal antibody against EGFR and subsequently conjugated it with the NIR
Cy5.5 dye to test for immunophotodiagnostic properties for oral precancer and as a surrogate
marker for disease progression.93 For this work, they used this probe to image a hamster cheek
pouch carcinogenic model in vivo.

While they were successful in producing a probe that

specifically labeled the tumor site and provided high contrast, the amount of time for the
maximum contrast was rather high (between 4 to 8 days).

Rosenthal et al. similarly used an

EGFR-Cy5.5 probe to image in vivo head and neck squamous cell carcinomas (HNSCC) in
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xenografts in mice.94

They were also able to localize tumor sites using fluorescence imaging at

24, 48, and 72 hours after injection of the probe.

Terwisscha et al. labeled antibodies for

vascular endothelial growth factor (VEGF) and human epidermal growth factor (HER) 2 with the
NIR dye IRDye 800CW for a proof of concept in intraoperative tumor detection in xenograftbearing mice.95

While they were able to obtain a submillimeter differentiation between tumor

tissue and healthy tissue, the SBR was only 1.93 — 2.92 after 6 days of injection.
1.2.4

Aptamer-Based Sensors
One optical imaging modality that is still in its infancy is that based on aptamers as

molecular

fluorescent

beacons.

Aptamers

are

single-stranded

ribonucleic

acids

or

deoxyribonucleic acids (RNA or DNA) that adopt unique conformations due to intermolecular
forces.13

Thanks to their extra small size, polyanionic nature, and diminished immunogenicity,

aptamers can provide rapid tissue penetration and uptake, high affinity for specific epitopes,
shorter residence in blood and non-target organs, and higher target accumulation. Compared to
antibodies, they are economical, synthetically reproducible, and can easily be conjugated with
signaling molecules without altering their binding affinity or specificity.96

Because of these

properties, aptamers are ideal targets for optical diagnostics and in vivo imaging.

Shi et al.

produced an always-on aptamer labeled with cyanine 5 (Cy5), denoted as TD05; that were
shown to have a strong binding affinity and high specificity for Ramos cells.96

This Cy5-TD05

aptamer system was found to provide high contrast in vivo in the B-cell lymphoma cell line
(Ramos cells) xenografts in mice.

After 4 to 5 hours, the unbound, always-on Cy5-TD05 was

removed via the blood stream, leaving behind fluorescent probe-enriched tumors. In comparison
to a negative control probe that produced a signal-to-background ratio (SBR) of 9.77 in the
Ramos xenografts, a SBR of 115.5 was obtained with Cy5-TD05.
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The same research group

produced an activatable aptamer probe (AAP) for in vivo tumor detection.13

To alleviate the

need for long diagnosis time due to high background signal from imaging with always-on
fluorophores, this design utilized an off-on fluorescence system in which the aptamer was
essentially nonfluorescent in the unbound state.

After binding to a specific marker, the aptamer

undergoes conformational change revealing probe fluorescence.

This “sgc8” aptamer consisted

of three fragments: the cancer-targeting aptamer sequence (A-strand), unreactive poly-T linker
(T-strand), and a short DNA recognition sequence (C-strand) complementary to part of the Astrand; this resulted in an aptamer stem-loop hairpin structure that opens up upon specifically
binding to the cell membrane protein kinase-7 (PTK7), Figure 1.8.97

Figure 1.8. Schematic representation of the novel strategy for in vivo cancer imaging using an
activatable aptamer probe (AAP) based on cell membrane protein-triggered conformation
alteration. The AAP consists of three fragments: a cancer-targeted aptamer sequence (A-strand),
a poly-T linker (T-strand), and a short DNA sequence (C-strand) complementary to a part of the
A-strand, with a fluorophore and a quencher attached at either terminus. In the absence of a
target, the AAP adopts a hairpin structure, resulting in quenched fluorescence. When the probe is
bound to membrane receptors of the target cancer cell, its conformation is altered, thus resulting
in an activated fluorescence signal; from Shi et al. (2011).13
Attached to one terminus is the fluorophore fluorescein-5(6)-carbonyl (FAM) and the
other terminus contains the quencher BHQ1, producing a Förster resonance energy transfer
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(FRET) quenching mechanism prior to activation binding by PTK7. Though the tumors could be
easily observed via fluorescence optical imaging in vivo using xenografts in mice, fluorescence
signal was prevalent throughout the entire body after 15 minutes.

This leads to one of the

downsides of aptamer imaging, which is the instability while circulating in the blood stream.
Only after sufficient time has passed to remove the non-specifically activated aptamer probe, can
it be possible to obtain high enough contrast for tumor detection.

Nonetheless, their studies

indicated substantial tumor fluorescence even 120 minutes after injection with minimal signal
appearing after 180 minutes.
1.2.5

Peptide Motifs
Another route in the miniaturization of ligands for target-mediated imaging is the use of

short peptide sequences labeled with fluorophores.

The goal in this model is development of

short sequences (10 — 15 amino acids) without losing the specific target affinity of their
naturally derived counterparts (antibodies).27

The positives from this miniaturization process and

increased biodistribution and bioavailability, and decreased cost due to fewer steps needed to
synthesize the short sequences. However, use of such few amino acids yields a lower number of
fluorophores per target recognition moiety, leading to a lower fluorescence signal.

As with

antibodies, aptamers, and nanocarriers, the epitopes that have been most commonly studied for
peptide-mediated imaging are membrane bound and found to be overexpressed in tumor tissues.
One of the more commonly studied peptide sequences for in vivo and in vitro analysis is the
cyclic tripeptide arginine-glycine-aspartic acid, c(RGD), having been shown to have a high
specificity towards the transmembrane glycoprotein α v β 3 .62,

98-102

One of the methods used by

Jin et al. to improve the contrast capabilites with the c(RGD) peptide sequence is a single species
containing multiple copies of the same sequence.100 Here, they were able to tether four c(RGD)
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units to a single Cy5-labeled cyclic decapeptide platform called a regioselectively addressable
functionalized template (RAFT), Figure 1.9A.

Using cell lines transfected so as to be α v β 3 -

positive or α v β 3 -negative, they were able to obtain a higher contrast between the cell lines with
the RAFT-c(RGD) 4 Cy5-labeled unit compared to the single Cy5-labeled c(RGD) sequence.
From here, they used the labeling motif in a xenograft model containing both the negative and
positive cell lines, where RAFT-c(RGD) 4 afforded a SBR of 15.9 at four hours post-injection.
After the same time period, the c(RGD) yielded a SBR of 1.4.
Another peptide methodology for optical imaging involves the construct of an activatable
cell penetrating peptide (ACPP).103-105

Cell penetrating peptides (CPPs) were first discovered

from the HIV-1 Tat peptide,106 and it has since been discovered that multicationic oligomers107
are equally or more effective than Tat. These CPPs are essentially membrane translocation units
and can be directly conjugated to materials, which can then enter the cell through a non-receptor
mediated process.

Though this process is still mostly ambiguous, it is believed the peptides

adsorb to the cell surface through electrostatic interactions and enters the cell via endocytosis.
Jiang et al. synthesized an ACPP by attaching a CPP to a cleavable linker that was enzymatically
removable, Figure 1.9B.104
intracellularly.

This linker neutralized the CPP, preventing it from being taken up

The enzyme which they designed this linker to be activated by was a matrix

metalloproteinase (MMP), specifically MMP-2 and MMP-9, because they have been the most
characterized.

MMPs are extracellular proteases that are responsible for invasion, metastasis,

and the degradation of the extracellular matrix (ECM).108-110 To evaluate the ability of the ACPP
to label tumors in vivo, they created a xenograft model in mice with a cell line known to contain
MMPs and measured the fluorescence intensity at the tumor site from Cy5-labeled ACPPs.
After 50 minutes post-injection of the probe, the ACPPs were found to be mildly effective in
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labeling the tumors. The contrast index was calculated to be 2.1, while the contrast index for two
negative control peptide sequences was 1.3 and 1.5.

A

B
Recognition

Raft
Cy5-Label

Figure 1.9. Structure of RAFT-c(RGD) 4 . Schematic diagram of activatable CPPs. Cellular
uptake induced by a cationic peptide is blocked by a short stretch of acidic residues attached by a
cleavable linker. Once the linker is cleaved, the acidic inhibitory domain drifts away, and the
cationic CPP is free to carry its cargo into cells. From Granger et al. (2005) and Jiang et al.
(2004).99, 104
1.2.6

Small-Molecule Conjugates
An even more simplistic imaging scaffold involves the use of small-molecule targeted

probes.

From the probes listed above, small molecules are generally more cost effective, easier

to make, show better pharmacokinetic properties, higher biodistribution, and are often less
immunogenic.111

For optical imaging, these probes are generally conjugated with always-on

NIR fluorophores and target well-known tumor properties, such as prostate-specific membrane
antigen (PSMA),112-113 overexpression of folate receptors,111 hypoxia,114 and increased glucose
uptake.115 PSMA has been studied extensively116 for the detection of prostate cancer, because it
is a well-known biomarker (that consists of an extracellular domain) of prostate cancer and
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metastatic prostate cancer cells, and it has been detected even in neovasculature of a variety of
non-prostatic solid malignancies.113,

117-118

Chen et al. developed an inhibitor for the enzyme

active site of the extracellular domain portion of PSMA and labeled it with the NIR dye IRDye
800CW.112

To demonstrate this probe’s effectiveness, they created a xenograft mouse model

containing a cell line known to upregulate PSMA and another cell line that does not express
PSMA.

In vivo fluorescence imaging revealed substantial retention of the probe in the PSMA-

containing cell line after 20.5 hours post-injection and minimal signal from the negative cell line.
This positive fluorescent signal was observed 70.5 hours after injection. Tueng et al. synthesized
a folic acid-bearing molecule conjugated to an NIR dye for optical detection of ovarian cancer.111
Previous reports have demonstrated that membrane-bound folic acid receptors are highly
overexpressed in ovarian cancer cell lines.119-121 In this study, they used the probe to determine
the fate of the dye in vitro in an ovarian cancer cell line.

After 30 minutes of incubating the

cultured cells with the probe, it was confirmed the probe was taken up through a receptormediated endocytotic process and was localized in endosomes.

In vivo analysis was also

performed in a xenograft mouse model, where they determined that the probe could be optically
imaged one hour after injection, and its signal reached a plateau 24 hours after injection.
1.3

Activatable Fluorophores
Fluorescent probes have become a common tool for sensing biochemical processes,

diagnosing diseases, detection of hazardous materials, drug discovery, and sensing biological
environments.122

With intrusive fluorescence being fairly rare amongst most compounds,

fluorescence-based sensors are highly sensitive, while being economical, and easy to use.
Attachment of specific recognition units on fluorophores that perturb the photophysical
properties of the dye allows for the creation of unique probes that can be used to detect specific
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analytes.

A highly sensitive and selective probe can be created by having a good understanding

of the interaction between the recognition unit and the analyte being detected.

This receptor-

analyte interaction can consist of hydrogen bonding, π - π , donor-acceptor, electrostatic, and
hydrophobic/hydrophilic

interactions,

metal

coordination,

and

chemical

or

enzymatic

reaction.122-123 Various fluorogenic probes and their applications will be discussed below.
1.3.1

Detection of Metal Ions and pH Changes
One of the common probe types are those for the detection of metal species such as Hg2+,

MeHg+, Ag+, Pd0 , Pd2+, Pt2+, Pt4+, Cu+, Cu2+, Au+, and Au3+.122 This is in part due to the wide
use of metal-containing catalysts in industry that have the potential to leach into soils and water
sources as a results of spills and waste disposal. Here, these metal species have the potential to
make their way into drinking water and food sources and later into the bodies of people, where
they can cause damage to organs and even cause cancer. Having a specific and sensitive probe
helps in the detection of polluted water and food and aids in decontamination protocols after
industrial spills.

Since their inception by de Silva,124 photoinduced electron transfer (PeT)-based

probes have become common place in the fluorescence-based detection arena due to the ease of
changing their recognition and signal units.

These fluorophores are designed to have a relatively

long range interaction between the fluorophore and receptor moieties, and generally are of the
structural form fluorophore-linker-receptor.20

This system generally acts as an off-on (turn-on)

type probe. In the quenched state, electron transfer from the non-ionized receptor to the excited
fluorophore prevents the fluorophore’s excited electronic state from relaxing down via a photonemitting process.

Upon binding of the analyte, the receptor’s oxidation potential is perturbed.

This prevents the transfer of the electron to the excited fluorophore, thereby dequenching the
dye.

In a majority of PeT quenching probes using the fluorophore-linker-receptor structure, the
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receptor unit contains an aliphatic amine that can readily be protonated and deprotonated so as to
cause a shift in the amine oxidation potential.

4-amino-naphthalimide-based fluorophores have

become one of the most studied PeT fluorophores, due to their highly fluorescent nature resulting
from the “push-pull” internal charge transfer (ICT) mechanism and the aromatic amine that can
be easily conjugated with a wide variety of linkers and receptors, Figure 1.10.125

Figure 1.10. 4-amino-1,8-naphthalimide structure and schematic representation of the ICT
excited state within the 4-amino-1,8-naphthalimide fluorophore caused by a “push–pull” action.
From Duke et al. (2010).125
He et al. devised a 4-amino-naphthalimide probe to detect potassium in whole blood and
serum using a cryptand as the receptor unit.126 An ideal probe for detection of any metal cation
detector must possess: good selectivity against all other cationic species relative to the one under
study, good binding properties to the ligand, and little to no pH interference. Quenching of dye
fluorescence through PeT was achieved by its conjugation to the cryptand via a short benzyl
linker moiety. Their probe was found to be selective and sensitive to potassium, because smaller
cationic metal species are too small to properly bind to the cryptand ligand.

However, it was

observed that potassium could be displaced by high concentrations of sodium.

Also using a 4-

amino-naphthalimide

that

PeT

quenched

probe,

it

was

aqueous/physiological Zn2+ was possible, Gunnlaugsson et al.127
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demonstrated

detecting

This PeT probe used a simple

aromatic iminodiacetate receptor molecule for the selective detection of Zn2+.

While the probe

was amenable with PeT type quenching at physiological pH, there was a turn-on effect in
fluorescence at lower pH values between 2 and 5 due to the protonation of the tertiary amine of
the receptor. With that being the only drawback, the probe was found to be highly selective for
Zn2+ vs. Mg2+, Ca2+, Hg2+, and Cd2+; none of the latter produced increases in fluorescence.
Recently, another set of fluorogenic probes that exploits naphthalimide dyes are the
compounds of ratiometric and colorimetric probes.
probes are always fluorescent.

Rather than turning off and then on, these

However, their emission wavelength shifts in either a red or a

blue after binding of the target analyte to the receptor unit. The shift in wavelength is brought on
by a perturbation in the ICT mechanism by analyte binding, either through weakening or
strengthening of the “push-pull” characteristic.128

This is useful in that these reporters still

contain the sensitivity of off-on probes, but also provide the aesthetic appeal of a colorimetric
assay, thereby allowing for quantitative analysis using the ratios of the pre-/post-binding
fluorescence.129

Xu et al. developed this type of dye using a naphthalimide construct for the

detection of Zn2+.129 In a pH 7.0 acetonitrile/water (80/20) solution, it was found that their probe
red shifted from 537 nm to 593 nm with excitation at the isosbestic point (λ ex = 470 nm). The
quantum yield did decrease from pre-addition to post-addition of zinc, Φ = 0.33 and Φ = 0.14 for

λ em = 537 and λ em = 593 nm, respectively. This probe was also found to be quenched by the
addition of Cu2+, Co2+ and Zn2+, while Li+, Na+, Mg2+, Ca2+, Fe3+, Mn2+, Al3+, Cd2+, Hg2+, Ag+
and Pb2+ caused no change in the optical properties.129 Xu et al. also synthesized a Cu2+ probe in
which the fluorescence was red shifted from 518 nm to 592 nm in an ethanol/water (60/40)
solution, with no effect from pH, changes between 2.88 to 12.0.130 As seen in Figure 1.11, the
binding of Cu2+ deprotonates the two aromatic nitrogens on the naphthalene system, which in
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turn causes the electron-donating ability of the nitrogens to increase thereby shifting the
fluorescence to the red. However, the quantum yield for the red-shifted dye was very low, Φ =
0.14.

Figure 1.11.
(2005).130
1.3.2

Binding of Cu2+ and deprotonation of the two aromatic amines. From Xu et al.

Biologically Relevant Probes
As our knowledge of the biological and biochemical milieu increases, the ability to detect

the events and analytes that compose it also increases.

A majority of these processes and

molecules can be observed using fluorophores, due to the high sensitivity of fluorescent probes.
These events can include detection of thiols,131-133 hypoxia,134 intracellular hydrogen sulfide,135
and pH changes to label endosomes and lysosomes for fluorescence microscopy.128

These

probes can be designed based on a variety of mechanisms, from off-on to ratiometric, from
structural changes in the fluorophore that induce fluorescence, or altering the ICT of the probe.
With glutathione being the most abundant intracellular thiol that plays a major role in regulation,
structure, and function of proteins—as well as its association with heart disease, cancer, stroke,
and neurological disorders—it has been one of the most studied of the biochemical
compounds.131,

136-138

As with a majority of the thiol-sensing fluorophores, Pires et al. utilized a

disulfide bond as the receptor unit for glutathione detection.131
27

This probe is of the off-on

variety and consists of a rhodamine-110 base, di-conjugated with two disulfide-containing
receptor units.

This di-conjugation of both aromatic amines in rhodamine-110 creates a locked

form and prevents fluorescence.

After reduction of the disulfide bonds by glutathione, both

linkers underwent cyclization to leave behind the highly fluorescent rhodamine-110.

This probe

was found to be specific for glutathione when compared to a second similar probe that contains
no disulfide units; minimal change in the fluorescent signal was found when it was incubated
with glutathione.

Though this cyclization process can be relatively slow, they were able to

effectively image cells using confocal microscopy and used flow cytometry to detect the
presence of intracellular glutathione.
Tumor environments generally have a lower pH and are hypoxic compared to other
physiological environments. Drug resistance, poor progression-free survival, and metastasis have
also been linked to hypoxia.114,

134, 139-141

Recently, work has been performed to produce

fluorogenic probes that are selectively activated under hypoxic conditions so as to better
understand the tumor microenvironment and to detect tumors using optical imaging.

One of the

more common methodologies in fluorescent detection of hypoxia involves using a nitro-based
receptor group that can be easily reduced under hypoxic conditions.
amino-naphthalimide probe with a nitro-benzyl receptor unit.134

Cui et al. designed a 4When conjugated to the

naphthalimide dye, the receptor weakens the ICT of the fluorophore yielding a blue emission.
After reduction of the nitro-group, the receptor undergoes electron-cascade elimination, leaving
behind a non-conjugated 4-amino-naphthalimide having a red-shift fluorescence signal.

Their

irreversible and ratiometric/colorimetric probe was found to be selectively reduced by
nitroreductase versus thiol reducing species, such as glutathione, dithiothreitol, cysteine, and
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homocysteine.

In vitro analysis was performed using the A549 cell line, where it was proven

that the probe could differentiate between hypoxic tumors and normal tissues.
1.3.3

Fluorophore Activation by Enzymes
As mentioned above, with a better understanding of the micro-/macroenvironment and

biochemistry of diseases come better modalities for detecting and understanding these diseases.
One of the more common approaches is to tailor fluorogenic probes to be selectively activated by
enzymes that are over-expressed in specific diseases. These probes can be used for in vitro and
in vivo analysis, tumor resection, and even aid in drug design.

The ability to selectively

detect specific enzymes hinges on having in hand a stable receptor substrate that is activated
by only the enzyme in question.

To be able to relate this probe to in vitro and in vivo work,

the enzyme must be highly upregulated in the environment being studied and preferably be
non-existent in a majority of other tissues.
based probes,
turn, this leads
fluorophores.

Coupling this upregulated enzyme with fluorescence-

it is possible to obtain real-time information from the diseased environment. In
to better designed enzyme substrates, drug delivery systems, and even
Common enzymes being studied include matrix metalloproteinases,142 γ-

glutamyltranspeptidase (GGT),12 β -galactosidase,143 aldo-keto reductase,144-145 cathepsins,146-147
3α -hydroxysteroid dehydrogenases,148 N-acetyltransferase 2,149 cytochrome P450,19 PSMA,150
penicillin G acylase (PGA),151 esterase,17-18, 152 and caspase-3.153-154
The Raines group has performed a significant amount of research in rhodamine110-based
latent fluorophores that are activated by esterases17-18 and cytochrome P450.19 From this group,
multiple “proof-of-concept” type probes have been developed. In one such case, Watkins et al.
demonstrated an off-on rhodamine110 fluorophore that is conjugated to an esterase substrate and
also with a tag to label a haloalkane dehalogenase (HD) variant.18
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This esterase substrate

contains a trimethyl-lock unit, that after esterase activation, increases the rate at which the
activated substrate is cleaved from the fluorophore so as to leave behind the highly fluorescent
rhodamine dye.

The second unit conjugated to the rhodamine110 is a tag that upon hydrolysis

by HD forms a highly reactant species that covalently labels the HD proteins.

This probe was

able to rapidly (15 minutes) diffuse through the cell membrane, label HD, and become activated
by an esterase. In vitro analysis using confocal microscopy and the U2OS cell line demonstrated
that when in the quenched state, the probe displayed minimal background signal.

This allowed

for fluorescence imaging without having to perform time-consuming washing steps.

This type of

imaging has the potential to play a large part in in vivo and even clinical analysis using
fluorogenic probes.

Being able to covalently label enzymes with high selectively and using off-

on fluorophores that are activated by enzyme prevalent in all tissues could prove to be beneficial
in cancer detection by irreversibly labeling overexpressed enzymes with a latent fluorophore,
while all un-labeled and activated fluorophores can be rapidly removed from the body.
The Shabat research group has developed latent fluorophores to obtain a better design
and understanding of some drug delivery systems (DDSs).147,

155-158

These types of drugs are

activated in a specific target site so as to increase the effectiveness of the drug on the diseased
area while reducing harm to healthy tissue.

When using off-on fluorescent probes, it is possible

to obtain better DDS designs from the trigger system to the linker covalently attaching the trigger
to the drug molecule(s).

From the sensitivity of fluorescent probes, real-time information can be

obtained from the activation and drug release from DDSs when the fluorophore is the pseudodrug

in

the

DDSs

design.

This

can give

information involving

pharmacokinetics,

pharmacodynamics, cell permeation efficiencies and pathways, and mechanisms of activation. 147
One methodology for obtaining more efficient DDSs is use of a linker that connects the
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activatable unit to the drug and subsequently undergoes a rapid elimination; the self-eliminating
linker is sufficiently long to separate the activating unit far enough away from any bulky groups
that may hinder enzyme activation.

Shamis and Shabat developed a dendritic amplification DDS

in which six fluorescent probes were attached to a single activating unit.157 The trigger group in
this setup was cleaved by penicillin G acylase (PGA), and the six tryptophan signaling groups
were conjugated through an elaborate dendritic self-immolative linker system.

From this work,

it was observed that it is possible to obtain 100% release of the signaling unit after a single
activation event, though release occurred over a 48-hour period.
One of the nascent techniques for the detection of tumors is fluorescence-based optical
imaging.

By using highly fluorescent markers in vivo, it is possible to rapidly label tumor cells

and obtain accurate borders between cancerous tissue and healthy tissue, something that is very
difficult to do with small metastatic tumors when using conventional imaging methods.

Another

drawback to the current clinical imaging techniques is the limited ability to image during
surgery, thus not allowing real-time information to be provided to the surgeon resecting the
tumors.

Current fluorescent-dye cancer imaging applications use always-on probes, and as a

result, they require a substantial amount of time to allow for passive accumulatation in the tumor
site.

Removal of the un-accumulated dye is also essential so as to reduce the amount of

background fluorescence (increase the SBR).

Urano et al. have developed a rhodamine-based,

off-on fluorophore that is selectively activated by γ-glutamyltranspeptidase (GGT).12

This GGT

protein is a membrane-bound enzyme involved in glutathione homeostasis, and it has been found
to be expressed in a variety of ovarian cancer cell lines.

Using this probe, they were able to

within 10 minutes differentiate cell lines containing and devoid of GGT using confocal
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microscopy, and after 60 minutes using flow cytometry.

It was also possible to detect ovarian

tumors in xenograft mouse models using fluorescence imaging.
1.4

NAD(P)H:Quinone Oxidoreductase-1
NAD(P)H:quinone oxidoreductase-1 (NQO1, EC 1.6.99.2, DT-diaphorase) is a flavin-

based, two-electron reductase enzyme that is highly upregulated (20- to 80-fold increase with
respect to normal tissue) in a wide range of tumor cells, such as lung, colon, melanoma, ovarian,
prostate, and breast cancer.1, 3-4, 159-162 As a result, NQO1 has been the target of studies as a sitespecific trigger for quinone-containing prodrugs.15,

160, 163-165

However, there are no reports

demonstrating the use of a real-time, NQO1-activated fluorescent sensor for in vitro analysis or
in vivo tumor detection.
1.4.1

Origin and Enzymatic Mechanism
NQO1 was previously discovered in the laboratory of Lars Ernster and visiting professor

Franco Navazio in 1957 while they were studying the distribution of intracellular NAD-/NADPdependent dehydrogenases in soluble fractions of animal tissues.166-168

This enzyme was first

isolated from the cytosolic fractions of rat liver homogenates and was found to oxidize
diphosphopyridine nucleotide (DPNH, NADH) and triphosphopyridine nucleotide (TPNH,
NADPH) at equal rates, which is how the name “DT-diaphorase” was coined.169-171 While the
first uncharacteristic attribute of NQO1 was that it was nonspecific towards NADH and NADPH,
it was also different in that it was cytosolic and more active than diaphorase enzymes associated
with the mitochondria and microsomes.172 In 1962, Ernster et al. published a document detailing
NQO1 purification from the soluble fractions of rat-liver cytosol, and the enzymatic properties of
NQO1.173

Of note, it was determined that there was NQO1 activity in the microsomal and

mitochondrial centrifugation fractions.

However, these activities were 42% for the microsomal
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fraction and 28% for the mitochondrial fraction compared to the soluble fraction.

It was also

speculated that these activities could be due to contamination of the mitochondrial and
microsomal fractions.

It was mentioned that the quinoid species 2,6-dichlorophenolindolphenol

(DCPIP) and coenzyme Q 0 were suitable substrates for NQO1, while its reducing capabilities
against vitamin K 1 , vitamin K 2 , coenzyme Q 10 , cytochrome c, and cytochrome b 5 was
negligible.

It was also discovered that the rat NQO1 was strongly (and competitively) inhibited

by dicumarol, while its activity was enhanced in the presence of bovine serum albumin (BSA),
polyvinylpyrrolidone (PVP), certain phospholipids, and certain non-ionic detergents (Tween-20,
Tween-60, and Lubrol-W), as well as certain phospholipids.

Maximum enzymatic enhancement

with added BSA was found to be 3- to 15-fold versus without BSA. While it was found that
increased pH also slightly increased enzyme function, there was no defined optimum.
Since the first publication about purification and activity, extensive work has been
performed on NQO1 to better understand its structure, activation mechanism, biosynthesis, and
its role in humans and animals.170

It has since been found that the enzyme catalyzes the

2-electron reduction of quinones to hydroquinones, along with other quinoid species to their
reduced version.

Due to its catalytic mechanism, it has been labeled a detoxifying enzyme as it

reduces quinones to hydroquinones, as opposed to quinones being reduced by one electron to the
radical-containing semiquinones.174
also in plants and bacteria.175

NQO-enzymes have been found not only in animals, but

NQO1 and NQO2 are both found in mammals, while NQO3,

NQO4, and NQO5 are found in eubacteria, fungi, and archaebacteria, respectively. A mutated
version of NQO1 (NQO1*2) has been discovered in which a mutation at position 609 has
occurred, causing the enzyme to become inactive.2

NQO1 is most abundantly found in animal

liver tissue, and it is also found in the brain, heart, lung, kidney, small intestine, skeletal muscle,
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and mammary glands.170

But of most importance, NQO1 has been found to be upregulated in

cancerous tissues 20- to 80-fold compared to normal tissue of the same origin.

1, 3-4, 159-162

Interestingly, it has been noted that small cell lung carcinomas (SCLCs) have very little NQO1
activity when compared with that of normal tissue, while the difficult to treat non-small cell lung
carcinomas (NSCLCs) have been found to have highly elevated NQO1 activity.159

Figure 1.12. Mechanism of the obligatory two-electron reduction of benzoquinone (Q) by
rNQO1. The overall reaction is: NADH + Q + H+ to NAD+ + QH2 . From Li et al. (1995).
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X-ray crystallography has aided in determining the structures of NQO1 from rats
(rNQO1), mice (mNQO1), and humans (hNQO1).176-177 The human enzyme is a roughly 62 kDa
interlocking homodimer of 273 residues and contains one flavin adenine dinucleotide (FAD) per
monomer. Each NQO1 has two separate domaines, a catalytic domain with an α /β fold and a Cterminal domain that forms part of the binding site for the adenosine portion of NAD+.176 When
reducing the same substrate (vitamin K 3 , menadione), the human and mouse version are both
slower by a factor of two when compared to the rat version.176 The FAD units were found to
bind tightly in all three enzyme structures (mouse, human, and rat) and did not readily come off
in native conditions.

Though the residue differences between the three enzymes are only slightly

different, there is an 86% similarity between hNQO1 and rNQO1, and 94% similarity between
rNQO1 and mNQO1.

The proposed reduction mechanism (ping-pong) by Li et al. of rNQO1

reducing benzoquinone is shown in Figure 1.12.177 Here, the reduced NAD(P)H enters the active
site and reduces the FAD+ to FADH 2 via hydride transfer. After NAD+ leaves, the duroquinone
enters the active site and is reduced by the hydride from FADH 2 .
1.4.2

Intracellular Localization
Previous studies have shown the presence of NQO1 in microsomes (vesicles formed from

the smooth/rough endoplasmic reticulum (ER) after cell homogenization), mitochondria, Golgi
membranes, plasma membranes, and the largest amount (>90%) in the cytosol, in rat liver
cells.161,

178-181

40% of the microsomal NQO1 enzyme was found to be in the lumen, while the

rest was incorporated into the membrane. NQO1 content was determined by collecting cellular
organelles via preparative ultracentrifugation, where the total protein conten—NQO1 and all
other proteins—and NQO1 activity were determined for each fraction. Even though this method
did provide similar results for all experiments (highest activity was found in the cytosol and
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lower activity in the mitochondria, Golgi membrane, plasma membrane, and microsomes),
activity caused by cytosolic contamination of the fractions after centrifugation could not be
discounted.178-179,

182

NQO1 movement in rat liver cells was also determined by radioactive

labeling of amino acids that were injected into rats.178 It was found that 5 minutes after injection,
the highest enzyme activity was observed in the rough ER. NQO1 was then found to move into
the smooth ER after 20 minutes, where it began to leave within minutes.178 Cytosolic content
slowly increased, while mitochondrial NQO1 appeared to reach a maximum after 15 minutes.
No other readings were performed after thirty minutes, and the only compartments tested were
rough ER, smooth ER, mitochondria, and cytosol. Later, Winski et al. used confocal microscopy
and immunohistochemical labeling in fixed cells to determine the location of NQO1 in the
cytosol and nucleus of HT-29 (human colorectal adenocarcinoma) and H661 (human non-small
cell lung cancer) cells.183 This group also used immunoelectron microscopy to provide evidence
that the enzyme was not located in the mitochondria, Golgi, and endoplasmic reticulum.

Along

with the electron microscopy data showing a very slight signal in the mitochondria,
immunoelectron microscopy has its own drawbacks caused by a loss of antigenicity during the
freezing fixative step and also by embedding the cells in resin.183
1.4.3

NQO1-Based Prodrugs and Inhibitors for Cancer Treatment
To date, there has been extensive work taking advantage of the upregulated state of

hNQO1 in tumor cells with the development of xenobiotics,1-2,
and inhibitors.191-195

15, 162, 184-189

prodrugs,163,

165, 190

After a quinone species undergoes NQO1-catalyzed reduction to its

hydroquinone, the compound either becomes activated or deactivated.188

While NQO1 can

deactivate specific quinones to hydroquinones to prevent them from oxidatively damaging cells,
it can also activate quinoidal molecules by creating the reduced form that has a higher reactivity,
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such as alkylating agents that can damage DNA.

This conversion of a quinone to a bioreactive

alkylating agent has been essential in the design of a wide variety of xenobiotics for cancer
therapy.

Tailoring these activating substrates specifically for NQO1 allows for the creation of

drug compounds that become cytotoxic in the tumor tissues highly overexpressing the enzyme.
The most successful xenobiotic that can be activated by NQO1, is mitomycin C (MMC).188
MMC has been used as a cytotoxic agent since the 1960s, and has activity against lung, stomach,
head and neck, prostate, breast and bladder tumors, and is currently used in cancer therapies.160
MMC is an indolquinone that, after reduction, forms an alkylating species. This reactive species
is cross-linked to DNA, and thereby preventing replication.

Though MMC has been clinically

used, it is considered a poor substrate for hNQO1. This has led scientists to develop analogs of
MMC that are better substrates for hNQO1 and still possess the cytotoxic active nature. One of
the more effective analogues is EO9,15 and it was discovered to be reduced more rapidly by the
enzyme when compared to MMC.

But this compound failed in clinical trials due to kidney

toxicity and rapid plasma clearance.

A second type of NQO1-activatable xenobiotic was in the

form of an aziridinylbenzoquinone, specifically diaziquone (AZQ).160,

188

AZQ is also a DNA

alkylating agent found to be effective in cancer treatment, but it suffered due to pH-dependent
alkylation and poor enzymatic activity, and it failed in clinical trials as it did not supersede
therapy agents already in use.160

Hernick et al. synthesized a series of indolquinone prodrugs

containing phosphoramidate at either the 2- or 3-position of the indole ring.165

After reduction

by NQO1, the cytotoxic phosphoramidate was cleaved and could add to DNA.

Their work

discovered that leaving groups in the 2-position were excellent substrates for NQO1 and could be
correlated with cytotoxicity in vitro.

While 3-substituted prodrugs were potent inhibitors of the

enzyme, there was no correlation found in the cytotoxicity studies.
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One of the unique uses of NQO1 has been in the development of mechanism-based
inhibitors to aid in the treatment of pancreatic cancer.194 The reasoning behind this is to remove
the ability of NQO1 to use its chemoprotective nature in pancreatic tumor cells. Previous work
had shown that NQO1 was a superoxide scavenger and prevented the levels of superoxides in
pancreatic cancer cells from elevating.194,

196

Irreversibly inhibiting the enzyme would allow

these levels to increase, causing toxicity. Dicumarol is a well-known potent inhibitor for NQO1,
but it lacks solubility in aqueous media, is a reversible inhibitor against NAD(P)H, and is also
known to inhibit multiple enzymes.194

The mechanism-based inhibitor ES936 was developed

from an indolquinone that formed a highly reactive iminium ion species after NQO1
reduction.191,

194

Immediately after activation in the enzyme active site, the hydroquinone

undergoes an irreversible alkylation with a tyrosine residue, completely inhibiting the enzyme.
1.4.4

NQO1 Specific Latent Fluorophores
Though NQO1 has been studied extensively for the development and implementation of

xenobiotic drugs for cancer therapy due to its high level of overexpression in a large portion of
tumors of varying origin, there have never been fluorescent probes synthesized for in vitro and in
vivo analysis of NQO1-containing tumor cells.

However, there have been two off-on NQO1

activatable latent fluorophores developed by the Huang research group for the detection of
glucose in a NQO1-glucose dehydrogenase coupled assay.197

Thus, their main interest was in

analyzing the substrate specificity of the two latent fluorophores with NQO1.

The first probe

contained a rhodamine110-based dye that was di-conjugated with two trimethyl-locked
quinones, similar to that in Scheme 1.1.197-198

Their analysis of this fluorophore involved

performing enzyme assays with NQO1 and relating the increase in fluorescence to a known
concentration of rhodamine110, assuming rapid reduction and removal of both quinone units.
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This assumption is inherently problematic as it does not take into account the fluorescence signal
derived from the mono-conjugated rhodamine species that exists after reduction/removal of a
single quinone group.

This mono-conjugated species has half the fluorescence intensity

compared to rhodamine-110.17

Secondly, having two enzymatic activation steps to achieve the

final product is not beneficial in real-time analysis.

A second probe was synthesized by

conjugating the same trimethyl-locked quinone to an N,N’-dimethylethylenediamine linker
attached to a coumarin dye.198

This probe, even with a single quinone, lacks real-time analysis

due to the linker. Here, it takes two non-enzymatic events to reveal the fluorescent signal of the
coumarin dye, removal of the quinone and cyclization/removal of the linker.

This cyclization of

the diamine linker into an urea species is rather detrimental in obtaining a rapid analysis type
assay, as cyclization spacers can be plagued with long half-lives.199
1.5
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CHAPTER 2
SHEDDING LIGHT BY CANCER REDOX—HUMAN NAD(P)H:QUINONE
OXIDOREDUCTASE-1 ACTIVATION OF A CLOAKED FLUOROPHORE DYE *
2.1

Introduction
Reductase enzymes associated with cancer have become an active area of research due to

their presence being used to understand the cellular machinery of the disease and their potential
for activation of prodrugs for disease therapies.

NQO1 (DT-diaphorase, EC 1.6.99.2) is highly

upregulated in cancer cells1-3 and is found in the cytosol, Golgi complex, nucleus, mitochondria,
cellular membrane, and endoplasmic reticulum, as well as extracellularly.4-11

NQO1 catalyzes

the 2-electron reduction of quinones to their hydroquinones using NADH or NADPH as an
electron donor.12-13

As a result, NQO1 is a focal point for cancer therapies utilizing

bioactivatable prodrug quinones, including those that undergo rearrangement reactions14-15 and
quinones that are cleaved from a target drug upon reduction, thereby releasing the active drug
target.16-17

The lack of information on the effects of local environment on quinone prodrug

activation and target drug release has slowed progress in this arena.18-19

Thus, it is of great

importance to develop and understand the behavior of triggerable reporter molecules that may
allow for selective and sensitive detection of NQO1 activity and provide temporal and spatial
feedback on quinone reduction and target release.

Of the various routes to measure enzyme

activity, cloaked or latent fluorophores are particularly attractive due to their triggerable off-on
fluorescence.20-22

This off-on activation mechanism provides superior signal-to-background ratio

due to the low amount of signal the cloaked fluorophore gives off.23-24

Discussed here is the

delineation, synthesis, successful, and even unsuccessful use of a new cloaked reporter whose
fluorescence is vastly increased upon its efficient human NQO1-catalyzed reductive de-cloaking.
* Portions of this chapter appear previously as Silvers, W.; Payne, A; McCarley, R., Chem. Comm.
2011, 47 (40), 11264-11266. Reproduced by permission of The Royal Society of Chemistry. Article.
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Possible reasons for the unsuccessful use of this cloaked fluorophore in relation to in vitro
analysis of NQO1 are analyzed and discussed, so as to provide insight for the future design and
selection of fluorophores that may be created for cellular-based sensing.
2.2

Experimental Section

2.2.1

Materials and Methods
3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-dimethylpropionic

acid

(Q 3 PA,

1) and rhodamine 110 -morpholino urea (Rho-Morph) were prepared according to literature
procedures.21,

25

as received.

For column chromatography, a Biotage FlashMaster Personal (Biotage) was used

All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used

with pre-packed 10 g silica gel columns.

Fluorescence-based activity, quantum yield

determination, and stability studies were performed on a Perkin Elmer LS55 fluorescence
spectrometer in quartz cuvettes.

Enzyme assays were performed using black plastic 96-well

plates (BD Falcon brand) on a FLUOstar OPTIMA from BMG LABTECH.
were collected in CDCl3 on a Bruker AV-400 spectrometer and
in CDCl3 on a Varian system 700 spectrometer.

13

1

H-NMR spectra

C-NMR spectra were collected

All NMR experiments were performed in

deuterated solvents and the chemical shifts are reported in standard δ notation as parts per
million using tetramethylsilane as an internal standard.
2.2.2

Cell Culture
HT-29 (human colorectal adenocarcinoma), A549 (human non-small cell lung cancer

(NSCLC)), and H596 (human NSCLC) were all purchased from American Type Cell Culture.
HT-29 cells were cultured in McCoy’s 5A medium supplemented with 10% fetal bovine serum
(FBS) and 100 IU/mL penicillin-streptomycin.

A549 cells were cultured in F-12K medium

supplemented with 10% FBS and 100 IU/mL penicillin-streptomycin.
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H596 cells were cultured

in RPMI-1640 supplemented with 10% FBS and 100 IU/mL penicillin-streptomycin. Cells were
incubated at 37 °C in a humidified incubator containing 5% wt/vol carbon dioxide (CO 2 ).
Synthesis of Q 3 -Rho-Morph

2.2.3
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Scheme 2.1. Synthesis of Q 3 -Rho-Morph (1).
Rho-Morph 2 (53.6 mg, 0.121 mmol) was dissolved in anhydrous DMF (0.9 mL) and
anhydrous pyridine (0.6 mL) under Ar. To this was added EDCI (43.72 mg, 0.228 mmol) and
Q 3 PA 3 (74.91 mg, 0.299 mmol). This solution was stirred at room temperature for 24 hr.
Solvent was removed under reduced pressure and the resulting residue was purified using
column chromatography (1:1 DCM:ethyl acetate, Rf = 0.43) to give probe 1 as a yellow solid
(27.8 mg, 34 %). 1 H-NMR (400 MHz, CDCl3 ) δ (ppm): 1.51 (d, 4H, J = 4.2 Hz), 1.99 (d, 4H, J
= 4.2 Hz), 2.18 (s, 3H), 3.05 (s, 3H), 3.53 (d, 4H, J = 2.5 Hz), 3.75 (d, 4H, J = 2.4 Hz), 6.61 (m,
2H), 6.95 (d, 1H, J = 4.8 Hz), 7.02 (m, 3H), 7.39 (d, 1H, J = 4.9 Hz), 7.60 (m, 2H), 7.88 (s, 1H),
7.98 (d, 1H, J = 4.2 Hz).

13

C-NMR (175 MHz, CDCl3 ) δ (ppm): 12.2, 12.8, 14.3, 29.0, 38.4,

44.4, 50.2, 66.6, 83.4, 107.8, 107.8, 112.8, 114.0, 115.5, 115.8, 124.2, 125.0, 126.2, 128.2, 128.3,
129.9, 135.4, 138.1, 138.3, 139.9, 141.4, 143.4, 151.6, 151.7, 153.1, 154.9, 170.1, 170.9, 187.6,
191.5. ESI-MS: For C 39 H37 N 3 O 8 : calculated m/z = 676.2659 [M+H]+; observed m/z = 676.2656
[M+H]+; 0.4 ppm error.
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2.2.4

Stability of Q 3 -Rho-Morph Against Biological Reductants
Stability studies against biological reductants were performed with a final concentration

of probe 1 being 5.0 × 10−6 M, using quartz cuvettes (final volume of 3.0 mL) and a Perkin
Elmer LS55 spectrophotometer (λ ex = 490 nm and λ em = 520 nm). The buffer used was 0.1 M
PBS (pH = 7.4, 0.007% BSA, 0.1 M KCl). Stability against NADH was performed in a 100 ×
10−6 M solution of NADH, with and without the presence of human NQO1 (5 × 10−5 g); the
fluorescence intensity was monitored every 40 sec for 2.2 hr. Stability against biological
reductants was tested by adding enough reductant to achieve a 1.0 × 10-3 M concentration for
glutathione, ascorbic acid, and dithiothreitol, and 0.4 mM sodium dithionite, in a 5.0 × 10−6 M
solution of compound 1 in buffer. The fluorescence intensity was monitored every 0.5 min for 6 hr.
2.2.5

NQO1 Assay of Compound Q 3 -Rho-Morph

NQO1 assays for the conversion of probe 1 to dye 2 were performed by following
fluorescence intensity (excitation at 485 nm and emission at 520 nm) every minute for at least 20
minutes using a FLUOstar OPTIMA instrument and Falcon 96-well plates (black with clear
bottoms). Recombinant human NQO1 (Sigma-Aldrich) in pH 7.4, 0.1 M PBS and supplemented
with 0.007% bovine serum albumin (BSA) was used. Stock solutions of compound 1 were
prepared in ethanol and diluted in buffer to a final concentration between 2.5 × 10−6 and
60 × 10−6 M. Total volume per well was 200 × 10−6 L with a final NQO1 content of 1 × 10−5 g.
Assays were initiated by the instrument-injection of NADH so as to yield a final NADH
concentration of 100 × 10−6 M. The concentration of released 2 at any given time was
determined from a fluorescence intensity vs. concentration calibration curve (Figure 2.1) for dye
2 in pH 7.4, 0.1 M PBS and 0.007% BSA. Rate versus [1] curves were fitted with a non-linear

64

least-squares algorithm so as to obtain K m and V max values using the computer program from
Cleland.26
3000

Fluorescence (RFU)

2500
2000
1500
1000
500
0
0.0

0.5

1.0

1.5

2.0

2.5

[Rho-Morph] x 10 Μ
-6

Figure 2.1. Calibration curve of Rho-Morph in pH 7.4, 0.1 M PBS supplemented with 0.007%
BSA. Calibration was performed in a black clear bottom Falcon 96-well plate while exciting at
λ ex = 485 nm and observing the emission at λ em = 520 nm.
2.2.6

Q 3 -Rho-Morph Incubation in Cells and Post Incubation Analysis
A549, HT-29, and H596 cells were plated in sterile black plastic Falcon 96-well plates

overnight to allow the cells to adhere to the bottom of the wells.

Each cell line was plated in 4

different wells at ~95% confluency. The next day, the medium was removed and replaced with 10

µM Q 3 -Rho-Morph in DMEM/F-12K medium supplemented with 10% FBS. Fluorescence analysis
was performed using a FLUOStar Optima (BMG Labtech) at 37.0 °C scanning every 15 minutes for
16 hours, λ ex = 485 and λ em = 520 nm.
Post-analysis of the culture medium and cells was performed using the FLUOStar Optima,

λ ex = 485 and λ em = 520 nm. The old medium from the experiment was removed and placed into
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empty wells and fresh medium with no probe was added to the wells containing cells to analyze the
fluorescence intensities from the cells and medium separately.

2.2.7

Live Cell Confocal Imaging
Confocal fluorescence images were acquired with a Leica TCS SP2 tandem scanning

laser scanning microscope.
lens (1.25 NA).

Experiments were performed using a 40x oil immersion objective

Imaging of DRAQ5 (nuclear stain) and Q 3 -Rho-Morph—loaded cells was

accomplished using a sequential scanning method with excitation via a 488 nm laser and
collecting emitted light between 500 and 555 nm with a PMT voltage of 790 V. DRAQ5 was
excited using a 633 nm laser and emitted light collected between 650 to 750 nm with a PMT
voltage of 513 V.

Images were frame averaged 6 times. HT-29, A549, and H596 cells were

incubated overnight in black 35 x 10 mm, 22 mm well glass bottom dishes (Chemglass Life
Sciences) in its complete growth medium at 37 °C with 5% CO 2 . Prior to imaging, the medium
was removed and replaced with F-12K medium (containing no phenol red) maintained at 37 °C.
From a concentrated solution of Q 3 -Rho-Morph in DMSO, the probe was added directly to the
dish to give a concentration of 10 µM (while ensuring approximately 1% or less DMSO with
respect to medium).

Cells were incubated with Q 3 -Rho-Morph for varying amounts of time.

Five minutes prior to imaging, DRAQ5 was added from a stock solution in DMSO to give a
concentration of 3.0 µM. Background for all images was removed in the same fashion using the
Leica software LAS LF Lite. Image analysis was performed using ImageJ.
2.2.8

Formation of Dihydro-Rho-Morph
The reduction of Rho-Morph to Dihydro-Rho-Morph was carried out by mixing a 5 µM

solution of Rho-Morph in 0.1 M PBS with 7 mg NADH (final concentration of 3.3 mM) and
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observing the change in absorbance over time.

Spectra were collected every hour for 6 hours

between 400 and 600 nm on a Cary 50 Bio UV-Visible Spectrophotometer.
2.3

Results and Discussion

2.3.1

De-Cloaking of Q 3 -Rho-Morph
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Figure 2.2. Activation of cloaked fluorophore 1 by human NQO1 to yield the highly fluorescent
dye 2.
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The cloaked reporter Q 3 -Rho-Morph is based on two fundamental units, namely an Nmorpholino-capped rhodamine 221 and a quinone propionic acid trigger group (Q 3 PA),27 Figure
2.2. Formation of the de-cloaked Rho-Morph occurs by Q 3 PA trigger group removal, which is
composed of two steps. Reductive activation of the Q 3 PA trigger group of 1 can be initiated via
chemical27 or enzymatic routes to yield the trimethyl-locked25 hydroquinone that subsequently
undergoes self-removal to form the lactone and highly fluorescent 2. As previously reported, the
rate of lactone formation for the Q 3 PA trigger group is relatively fast in buffered aqueous media,
with a t 1/2 in the minutes time domain.28 We designed the cloaked reporter 1 such that there are
no concerns over removal of two trigger groups to yield the active reporter,29-30 nor are there
issues regarding additional slow chemical steps31 to signal the presence of hNQO1 activity.
To ensure an off-on cloaked reporter system was produced, the emission spectra and
quantum yield (Φ ) values of probe Q 3 -Rho-Morph and dye Rho-Morph were obtained in
aqueous media at physiological pH (0.1 M phosphate-buffered saline, PBS, pH = 7.4) using
Equation 2.1:
∫𝐹

Φ 𝐹 = Φ𝑆 �∫ 𝐹𝑒𝑚,𝐹 �
𝑒𝑚,𝑆

Equation 2.1

where Φ F is the quantum yield of the dye, Φ S is the quantum yield of the standard, F em,F is the
integration of the fluorescence spectrum of the dye, and F em,S is the integration of the
fluorescence spectrum for the standard.32

Fluorescein was used as the standard with a quantum

yield of Φ = 0.95.21 Q 3 -Rho-Morph exhibits little in the way of fluorescence emission as noted
by its spectrum in Figure 2.3 and quantum yield of 0.005. However, Rho-Morph is strongly
fluorescent with a quantum yield of 0.48, leading to a 96-fold difference in quantum efficiencies.
This significant difference in quantum yields is quite sufficient to classify this reporter system as
being off-on in nature.
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Figure 2.3. Fluorescence spectra of Q 3 -Rho-Morph 1 (blue line) and Rho-Morph 2 (red line) in
pH 7.4, 0.1 M PBS; concentrations of each were such so as to provide an absorbance of 0.047 at
465 nm. Excitation wavelength = 490 nm and emission wavelength = 520 nm.
2.3.2

Stability of Q 3 -Rho-Morph
To assess the selectivity of the de-cloaking of probe Q 3 -Rho-Morph, we investigated its

stability under physiological solution conditions in the presence of various adventitious, potential
reducing agents. Upon inspection of Figure 2.4, it is clear that probe 1 (5.0 × 10-6 M) is relatively
unaffected while in the presence of high concentrations (1 × 10-3 M, 100-fold excess) of various
reductants: ascorbic acid (AA, E 1/2 = 0.051 vs. SHE),33 glutathione (GSH, E 1/2 = -0.22 V),34 and
dithiothreitol (DTT, E 1/2 = -0.33 V).35 As a control, a strong reducing agent (sodium dithionite, 4
× 10-4 M final concentration) known to efficiently reduce the Q 3 PA trigger group was added to a
5.0 × 10-6 M solution of probe 1 to provide a signal for ~100% activation of the probe. GSH and
AA are found to have minimal effect (~3–4% activation at 8 min), while DTT caused a slightly
higher (~8%) increase in fluorescence. Based on these results, cloaked probe 1 is highly stable
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toward activation by possible biological interferents, such as glutathione that is known to be

% Maximum of S2O42- Stimulus

present at millimolar concentrations within cells and micromolar levels in the blood stream.36-37
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Figure 2.4. Fluorescence response of probe 1 (5.0 × 10-6 M) in pH 7.4, 0.1 M PBS while in the
presence of 1 × 10-3 M DTT, AA, and GSH relative to the complete activation of 1 by 4 × 10-4 M
sodium dithionite.
We determined the ability of hNQO1 to de-cloak 1 to yield dye 2 upon activation of the
Q 3 PA trigger group (E p,c = -0.28 V vs. SHE). Solutions of probe 1 exhibited a rapid increase in
fluorescence after hNQO1 (5.0 × 10-5 g) was added (Figure 2.5), pointing to efficient de-cloaking
of the dye by hNQO1. Under the same conditions in the absence of hNQO1, i.e. an aqueous
solution containing only β -NADH cofactor (1 × 10-4 M; E 1/2 = -0.31 V)38 in 0.1 M PBS, there
was no evidence for hydrolytic or NADH-based activation of cloaked reporter 1. Thus, cloaked
reporter 1 can be used to quickly detect hNQO1 activity.
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Figure 2.5. Fluorescent signal from the activation of 5.0 × 10-6 M 1 in a 1 × 10-4 M solution of
NADH in the presence and absence of recombinant human NQO1 (5 × 10-5 g, 8 × 10-6 M) in pH
7.4, 0.1 M PBS with 0.007% bovine serum albumin. Excitation wavelength = 490 nm and
emission wavelength = 520 nm.
2.3.3

Q 3 -Rho-Morph Substrate Analysis With hNQO1
In order to quantitatively evaluate the ability of hNQO1 to activate 1 with time, kinetic

parameters were obtained for hNQO1 based on the release of 2. The amount of 2 present was
obtained by observing the intensity of its fluorescence (λ ex = 485 nm and λ em = 520 nm) and
converting this to a concentration by use of a calibration curve for 2, which was linear over the
concentration ranges studied. Monitoring fluorescent product formation is a common approach
for enzymatic activation of cloaked fluorophores.22,

39

The initial rate of product formation V was

obtained for 2 concentrations of 2.5–60 × 10-6 M and then plotted as a function of [1], as
presented in Figure 2.6. Kinetic parameters were determined by non-linear, least-squares fitting
of the data in Figure 2.6 to the Michaelis–Menten equation.26 The Michaelis constant (K m ) value
was determined to be 23.7 ± 3.5 µM, maximum velocity (V max ) was 0.00214 ± 0.00013 µmol
min-1 mg·NQO1-1 , catalytic activity (k cat ) was 0.00110 ± 0.00007 sec,-1 catalytic efficiency
(k cat /K m ) was 46.4 ± 7.4 M-1 sec-1 , and the error from fitting was χ2 =5.6 × 10-9 ,. Based on the
values for V max , k cat , and k cat /K m , it can be concluded that Q 3 -Rho-Morph is a good substrate
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(though not the best) for hNQO1 when compared to substrates containing the same Q 3 PA
activatable group.17,

29, 31

The cause for lower catalytic efficiency could be in part due to the

bulky rhodamine 110 species to which the Q 3 PA is directly conjugated.

This steric hindrance

would potentially slow the rate at which Q 3 -Rho-Morph moves into the active site in hNQO1.
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Figure 2.6. Kinetic plot for recombinant human NQO1 (1 × 10-5 g) towards 1 in pH 7.4, 0.1 M
PBS, and 0.007% bovine serum albumin. Solid blue line indicates best fit to Michaelis–Menten
equation.
2.3.4

hNQO1 Sensor Using Q 3 -Rho-Morph
With the evidence that Q 3 -Rho-Morph is activated by hNQO1, is stable towards certain

biological reductants, and has a large 96-fold fluorescence enhancement (FE), we set out to
determine if the dye could be used as an hNQO1 sensor in cancer cells. First, a simple test was
used to determine if cells known to contain hNQO1 could significantly activate Q 3 -Rho-Morph
when compared to cells devoid of hNQO1. The three cell lines used had been previously studied
for hNQO1 activity and are: HT-29 (colorectal carcinoma, hNQO1-positive), A549 (NSCLC,
hNQO1-positive), and H596 (NSCLC, hNQO1-negative).14,

40

When in the presence of 10 µM

Q 3 -Rho-Morph, an almost linear increasing fluorescence was found for not only the two positive
72

cells lines, but also the negative cell and even the medium (though only a 1.5-fold increase),
Figure 2.7.
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Figure 2.7. Following the fluorescence in HT-29 cells (red, dot), A549 cells (blue, solid), H596
cells (green, dash), and DMEM/F-12K with 10% fetal bovine serum (black, dot-dot, dash) when
in the presence of 10 µM Q 3 -Rho-Morph. Samples were scanned every 15 minutes over a 16
hour period with λ ex = 485 nm and λ em = 520 nm.
Based on the fact that there was a significant increase in signal over 16 hours for A549
(4.8-fold increase) and HT-29 (3.3-fold increase), it is believed that the increase is due to
conversion of Q 3 -Rho-Morph to Rho-Morph.

Over the same time period, an increase in

fluorescence was also found for the negative cell line H596 (2.6-fold increase) and also the dye
in complete DMEM/F-12K growth medium (1.6-fold increase).
To again assess the applicability of Q 3 -Rho-Morph as a rapid sensor for hNQO1 in
cancer cells, confocal imaging was performed on HT-29, A549, and H596 cells lines after
incubation with the probe.

Cells were always cultured overnight and plated at ~80% confluency

in the imaging dishes to allow for adhesion of the cells to the glass bottom.

To simplify the

imaging process, the culture medium containing dye was never removed from the wells and the
cells were never washed prior to observing the cells under the confocal microscope.
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The first

complication was found to be the amount of weak signal arising intracellularly. It was found that
the only way to achieve usable images was to use a high (790 V) PMT detector voltage, which
also produced signal from the probe in the medium.

Secondly, there was no differentiation

between the two cell lines (HT-29 and A549) known to contain hNQO1 and the cell line (H596)
which is devoid of the enzyme.

As seen in Figure 2.8, all three cell lines essentially look the

same (with minimal background removed using the imaging software) with respect to the
amount of green signal, which is derived from the excitation at 488 nm. The nuclei are blue in
each image.

Using the program ImageJ, the relative average cytosolic intensities for each cell

line were determined from the images in Figure 2.8. HT-29 (A) was found to have an average
intensity at 11.4, A549 (B) at 22.5, and H596 (C) at 17.1. These values confirm the fact that
A549 and HT-29 cannot be distinguished from H596.

This type of experiment was performed

multiple times with varying concentrations of Q 3 -Rho-Morph and varying incubation times, all
leading to similar images where no cell line could be labeled as “hNQO1-positive” or “hNQO1negative”.

A

B

C

Figure 2.8. Confocal imaging of HT-29 (A), A549 (B), and H596 (C) cells after a one hour
incubation with 10 µM Q 3 -Rho-Morph (green). Cells were all stained with 3.0 µM DRAQ5,
which is labeled in blue. Cells were imaged using 488 nm and 633 nm lasers to excite RhoMorph and DRAQ5, respectively.
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It was next illustrated that changing certain variables, such as incubation time, would lead
to similar results as seen in Figure 2.8. To do this, we incubated A549 and H596 cells with Q 3 Rho-Morph for 24 and 72 hours and obtained fluorescence images at each time period, Figure
2.9.

A

B

C

D

Figure 2.9. Confocal imaging of A549 cells after 24 and 72 hours of incubating with Q 3 -RhoMorph, A and B respectively, and H596 cells after 24 and 72 hours of incubating with Q 3 -rhoMorph, C and D respectively. Cells were imaged while exciting at 488 nm, represented by green
in each image.
It is clearly visible that the intensities in both cell lines increase from 24 to 72 hours, but
A549 never obtains substantially more signal than H596.

Using ImageJ to analyze the cytosolic

signal of each image, values for A549 at 24 hours and 72 hours were found to be 18.0 and 32.9,
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respectively.

Values for H596 at 24 hours and 72 hours were found to be 11.3 and 23.2,

respectively.

Also of note, the PMT detector voltage was left the same between the two

incubation periods which indicates a lack of formation or accumulation of Rho-Morph in the
cells.

This lack of intense signal leads me to believe there is either no (or very little) activation

to Rho-Morph, degradation of Q 3 -Rho-Morph, or efflux/quenching of Rho-Morph in the hNQO1
positive cell lines.
2.3.5

Elucidating the Negatives of Q 3 -Rho-Morph
To try and elucidate the mechanism(s) for which Q 3 -Rho-Morph failed to be used as an

in vitro hNQO1 sensor, several experiments were performed involving stability of Q 3 -RhoMorph and Rho-Morph.

First, the stability of Q 3 -Rho-Morph was tested at a low pH (4.0) to

determine if there was any degradation due to the low pH of acidic compartments in cells. A 10

µM solution of Q 3 -Rho-Morph was made in pH 4.0, 0.1 M PBS and fluorescence was checked
for 16 hours while exciting at 485 nm and following the emission at 520 nm. As seen in Figure
2.10, there is no significant change in fluorescence. In fact, the change that does occur is similar
to the results in Figure 2.4. Over the first 15 minutes, an increase of 4% is seen and 14% over
the first hour. This provides evidence that low intracellular pH would not degrade the sensor and
thus lead to little gain in fluorescence when imaging.
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Figure 2.10. Following the fluorescence of Q 3 -Rho-Morph over time while in pH 4.0, 0.1 M
PBS. λ ex = 485 nm and λ em = 520, scanning every 15 minutes for 16 hours.
The next goal was to try and determine the fate of Rho-Morph after its production in the
hNQO1-positive cell lines.

Though Q 3 -Rho-Morph was found to be stable towards biological

reductants, Rho-Morph was tested against one of the more prevalent intracellular reducing
species, NADH.

NADH has a reduction potential of -0.31 V and the concentration in human

breast cancer cells has been calculated to be 168 ± 49 µM.38,

41

A 5 µM solution of Rho-Morph

was made up in pH 7.4, 0.1 M PBS, and NADH was added to give a concentration of 100 µM.
From this, fluorescence intensity was followed over time. In Figure 2.11, it is seen that NADH
rapidly reduces the signal from Rho-Morph. One hour after the addition of NADH, Rho-Morph
produces 30% less fluorescence.

This is a significant reduction in signal with a relatively low

NADH concentration, as compared to intracellular concentrations.
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Figure 2.11. Observing the signal reduction of a 5 µM solution of Rho-Morph in pH 7.4, 0.1 M
PBS with 100 µM NADH. Sample was scanned every 5 minutes over 5 hours, λ ex = 490 nm and
λ em = 520 nm.
Observing that the signal decreases over time after NADH is introduced also shows the
reduction of fluorescence of Rho-Morph is most likely not a photophysical property, but rather a
chemical interaction between the two compounds.

Similar nonfluorescent “dihydro” forms of

rhodamine and fluorescein dyes were found to have been patented and are currently
commercially available for the detection of intracellular reactive oxygen species.42

These dyes

were synthesized by the reduction of the parent dye via sodium borohydride in buffer until no
absorption band (λ = 490 nm) appeared, after which the dye was diluted as is and used
immediately in cell studies.

After being re-oxidized, these sensors regained their fluorescence.

It was postulated Rho-Morph was undergoing a similar reduction by NADH, Scheme 2.2.
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Scheme 2.2. Possible conversion of the quinoid version of Rho-Morph to a Dihydro-Rho-Morph
species via reduction by NADH.
To test this theory, a 5 µM solution of Rho-Morph in pH 7.4, 0.1 M PBS was added
sufficient NADH to give a final concentration of 3.3 mM.

The absorbance spectrum was

scanned over a 6 hour period in one hour intervals in the region where Rho-Morph is excited
(400-600 nm), Figure 2.12.

As seen below, the absorbance diminished to 3% of its original

absorbance at λ = 485. After the first hour, the absorbance at λ = 485 nm had dropped by 43%,
and 71% after the first 2 hours. This observation of reduction and absorbance decrease leads to
the conclusion that the Dihydro-Rho-Morph is not be fluorescent, similar to the commercially
available dyes.
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Figure 2.12. Observing the reduction and change in absorbance of Rho-Morph to Dihydro-RhoMorph via reduction in a 3.3 mM solution of NADH.
Though NADH is not as strong as a reducing agent as sodium borohydride, we
speculated the electron withdrawing urea group on Rho-Morph would sufficiently lower the
reduction potential of the dye allowing Rho-Morph to be reduced by NADH at higher
concentrations.

This formation of Dihydro-Rho-Morph intracellularly would be in competition

with the formation of Rho-Morph from Q 3 -Rho-Morph and the re-oxidation of Dihydro-RhoMorph into its fluorescent form.
A reason why Q 3 -Rho-Morph possibly failed as an in vitro sensor could be due to the
specific form that Rho-Morph exists while being intracellular that was published by Watkins et
al.43

Their group discovered a perturbation in the equilibrium of the rhodamine quinoid and

lactone species when rhodamine was mono-conjugated with an electron withdrawing group, such
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as a urea bond, Scheme 2.3.
fluorescent lactone form.

This created a shift towards the cell membrane permeant/non-

This issue explains the lack of dye accumulation in the hNQO1-

positive cell lines and the need to image with a high PMT detector voltage.

This theory was

tested by removing the medium from the wells after the end of experiment in Figure 2.7 and
measuring the fluorescence of the medium and cells and comparing the two values to determine
if a majority of the dye signal was present in medium.

At the end of that experiment, wells

containing A549 cells and the used medium had an average intensity of 33,347; HT-29 had
26,541, and 17,758 relative fluorescence units (RFU).

After removing the old medium and

placing it in an empty well, the signal arising from the cells with fresh medium and also the old
medium by itself was measured, with the results in Table 2.1.

From the data collected, it was

found that the intensity of A549 cells was only 3.4% of that from the used medium.

Similar

results were found for HT-29 and H596 cells, 7.4% and 6.0% respectively. First observations
were that the intensities were higher when measuring the fluorescence from the old medium with
no cells compared to the values obtained at the end of the incubation period with the cells. This
can be attributed to the bottom-read nature of the FLUOStar Optima and that the cell layer was
most likely acting as a filter between the detector and medium.

It is also clear that the signal

attributed to the cells with fresh medium was low for all cell lines, demonstrating the lack of
accumulation of Rho-Morph in each cell line.

While the signal from the old A549 medium is

significantly higher (55%) than that derived from the H596 cells, the HT-29 medium signal was
only 15% higher than that of H596.

These old medium intensities are similar to what was seen

in Figure 2.7, leading to a very plausible efflux mechanism to which Rho-Morph shifts to the
lactone form and moves from intracellular to extracellular.
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Table 2.1. Summary of fluorescence intensities in cells and culture medium after incubating in
culture medium containing 10 µM Q 3 -Rho-Morph for 16 hours. λ ex = 485 and λ em = 520 nm.
Units are in RFU.
Cells Only
A549 H596 HT-29
1804
1275
1835

2.4

Old Medium
A549
H596
HT-29
46888
21184
24890

Conclusions
Based on the data presented here, we have clearly demonstrated that the turning on (de-

cloaking) of the new cloaked

fluorophore Q 3 -Rho-Morph under physiological solution

conditions is sensitive to the presence of hNQO1, while the de-cloaking is sufficiently selective
with regard to the presence of potential interferents.

Importantly, Q 3 -Rho-Morph was designed

to utilize ‘‘single-hit’’ enzyme activation; in other words, only a single stimulus is required to
cause signal transduction (the release of Rho-Morph).

In addition, the signal revealing process

for the activated species is efficient, as it requires only one step (hydroquinone lactonization).
Though the biological stability of Q 3 -Rho-Morph and the photophysical properties of RhoMorph were promising as an in vitro sensor, there were unforeseen pitfalls with the Rho-Morph
scaffold that led to the inability to use Q 3 -Rho-Morph in cellular studies. One shortcoming was
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found to be the formation of a nonfluorescent Dihydro-Rho-Morph species following the
reduction of Rho-Morph by NADH.

Another issue with Rho-Morph was published by Watkins

et al.43 and leads to the postulation that in the presence of polar media, Rho-Morph favors a
nonfluorescent/cell membrane permeable lactone form over the fluorescent quinoid form.

This

is due to the electron withdrawing urea group on one side of the xanthene ring system. Though
Q 3 -Rho-Morph is not suitable for intracellular hNQO1 sensing, it is quite useful for enzymology
studies with hNQO1 due to the single-hit activation mechanism and the large FE from the
quenched dye to the de-quenched dye. It also has provided invaluable information in regards to
the future design of cloaked fluorescent sensors, regardless of the specific activation mechanism.
2.5
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CHAPTER 3
NAPHTHALIMIDE-BASED CLOAKED FLUOROPHORE FOR THE RAPID AND
FACILE DETECTION OF HUMAN NAD(P)H:QUINONE OXIDOREDUCTASE-1 IN
TUMOR CELLS

3.1

Introduction
To obtain the best prognosis possible in dealing with cancer, it is desirable to have an

accurate and early diagnosis and resect as much tumor(s) as possible.1-2 This is conceivable by
having a highly sensitive and selective probe that has the ability to detect circulating cancer cells
or rapidly give proof-positive results from a biopsy of ex vivo tumors.

By providing real-time

information on the tumor microenvironment, a better determination of pharmacodynamic effect
of drugs on the specific tumor cells can be obtained.

This will lead to better prediction and

evaluation of which therapy should be undertaken.3

With complete resection of tumors

correlating to “curing” patients, it is highly important to determine small tumor locations and
accurate borders between tumors and healthy tissues.2,

4-5

Fluorescence-guided surgical resection

has been of great interest recently with the production of several varieties of activatable
fluorophores ranging from cell penetrating peptides, aptamers, enzyme catalyzed fluorophores,
and biosynthetically produced fluorophores.6-9

Previously reported enzyme activatable probes

for tumor detection are primarily activated by: cathepsin, caspase, γ-glutamyltranspeptidase, and
matrix metalloproteinase.8,

10-12

By selecting a specific enzyme biomarker with unique properties

that is highly upregulated in tumor cells from a wide range of origin, it is possible to produce a
single sensor with multifunctional capabilities.
Multifunctional fluorescent-based sensors have recently become a powerful tool in the
treatment and diagnosis of cancer, given their specific and sensitive nature.13

The use of smart

off-on sensors, where the fluorescence is quenched and only revealed after a specific stimulus,
87

provide a more ideal system due to the sensitivity, low signal-to-background ratio, specificity,
more economical when using fewer synthetic steps and inexpensive starting materials, and
stability in biological environments.13-14

This strategy can utilize the upregulation of specific

enzymes in tumor cells with respect to normal tissue.

Enzymatically cleavable groups can be

conjugated directly to fluorophores causing a quenching effect of the fluorescent signal, with the
subsequent generation of the fluorescent species upon the removal of the cleavable group. This
enzyme catalyzed off-on sensor is more advantageous than receptor-mediated diagnosis, which
commonly employs “always-on” probes containing high background
considerable time to achieve a desirable background-to-signal ratio.8,

15

signal and require

Ideally, the sensor would

be of low molecular weight (<1000 Da) and be hydrophobic in nature to facilitate diffusion and
retention in tumor cells.13
One of the more prolific upregulated cytosolic enzymes present in a wide variety of
tumor cells is NAD(P)H:quinone oxidoreductase-1 (NQO1), which is widely distributed and
found to be over-expressed 2- to 50-fold (with respect to normal tissue) in human tumors ranging
from colon, breast, lung (small cell and non-small cell lung cancers), liver, stomach, kidney,
head/neck, to ovarian carcinomas.16-17

This flavoprotein catalyzes the two-electron reduction of

quinones and quinoid species, preventing the formation of reactive oxygen species (ROS) from
the single-electron reduction of quinones to semiquinones.

Given its over-expression in tumor

cells and its enzyme catalyzing reaction, NQO1 has been previously studied as a bioactivator for
chemotherapeutics.18-19

Outside of its enzymatic characterization, NQO1 is a multitasking

enzyme and has also been associated as being a gatekeeper for the 20S proteasome pathway and,
though the exact mechanism is still unclear, stabilizing the tumor suppressors p53, p73α , and
p33.20 The suppressor p53 is activated under conditions of stress which initiates cell cycle arrest,
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DNA repair, and apoptosis and is also important in suppressing tumor initiation and growth.
More than half of all human cancers have been known to have lost p53 function.21

NQO1

Q3 NN
NN
Lactone

Tumor Cell

Figure 3.1. Passive diffusion of the hNQO1 sensor (Q 3 NN) across the cell membrane, followed
by enzymatic activation with subsequent release of the fluorescent dye NN.
3.2

Experimental Section
Here, the design, characterization, and utilization of a first generation activatable cloaked

fluorophore enzymatically activated by NQO1 is reported.

This fluorophore contains an

activatable trimethyl-locked quinone subunit that, after reduction, rapidly cyclizes leaving behind
the reporter fluorophore. This sensor employs a unique two-step quenching mechanism of
photoinduced electron transfer (PeT), allowing it to be highly sensitive and specific for NQO1
activity.

This two-step PeT exploits the two-electron reduction from NQO1 and only reveals its

fluorescence after quinone elimination, circumventing false activation from non-specific singleelectron reduction of the quinone unit.

The sensor is hydrophobic, small in molecular weight,

and neutral in charge, allowing it to easily passively diffuse into the cytosol of tumor cells,
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Figure 3.1.

The product dye contains a naphthalimide scaffold and is fluorescent via a push-pull

internal charge transfer (ICT) mechanism.
aqueous media and is cationic at neutral pH.

The dye was found to be highly fluorescent in
Given its rapid activation mechanism, it provides

real-time tumor cell analysis and allows for quick tumor cell differentiation with respect to
NQO1.
3.2.1

Materials and Methods
3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-propionic acid (Q 1 PA, 6A) and

3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-dimethylpropionic
were prepared according to literature procedures.22
Aldrich or Fisher Scientific and used as received.

acid

(Q 3 PA,

6B)

All chemicals were purchased from SigmaFor column chromatography, a Biotage

FlashMaster Personal was used with 50 g SNAP silica columns (Biotage).

Thin layer

chromatography was performed on aluminum-backed 60 F254 silica plates from EMD
Chemicals, INC.

1

H- and

13

C-NMR spectra were collected at room temperature on a Bruker AV-

400 or a Varian system 700 spectrometer. All NMR experiments were performed in deuterated
solvents and the chemical shifts are reported in standard δ notation as parts per million using
tetramethylsilane as an internal standard.

Peaks in NMR are listed as either, singlet (s), doublet

(d), doublet of doublets (dd) triplet (t), multiplet (m), two triplets (2t) while coupling constants
(J) are reported in Hertz (Hz).

Mass spectral analyses were carried out using an Agilent 6210

ESI-TOF.
3.2.2

Cell Culture
HT-29 (human colorectal adenocarcinoma), A549 (human NSCLC), H596 (human

NSCLC), and H446 (human small cell lung cancer) were all purchased from American Type Cell
Culture.

HT-29 cells were cultured in McCoy’s 5A medium supplemented with 10% fetal
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bovine serum (FBS) and 100 IU/mL penicillin-streptomycin. A549 cells were cultured in F-12K
medium supplemented with 10% FBS and 100 IU/mL penicillin-streptomycin.

H596 were

cultured in RPMI-1640 supplemented with 10% FBS and 100 IU/mL penicillin-streptomycin.
H446 were cultured in RPMI-1640 supplemented with 10% FBS and 100 IU/mL penicillinstreptomycin.

Cells were incubated at 37 °C in a humidified incubator containing 5% wt/vol

carbon dioxide (CO 2 ).
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Scheme 3.1. Synthetic route for Q 3 NN and Q 1 NN.
3.2.3

4-Amino-9-(N-butyl)-1,8-naphthalimide Synthesis
4-amino-1,8-napthalic anhydride 1 (0.99 g, 4.64 mmol) was dissolved in 250 mL 200

proof ethanol under a nitrogen atmosphere and brought to reflux. To this solution was added 1butylamine (1.84 mL, 18.56 mmol), after which the reaction was left to reflux for 14 hours.
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After cooling to room temperature, the solvent was removed under reduced pressure and the
crude product was collected and purified using silica gel column chromatography (2:1
DCM:EtOAc, Rf = 0.38).

Product was collected, solvent removed, and the solid was placed

under high vacuum yielding 2 as a yellow solid (0.95 g, 77%).

1

H-NMR (DMSO-d 6 , 400 MHz):

δ 8.57 (1H, d, J = 8.3 Hz), 8.39 (1H, d, J = 7.2 Hz), 8.15 (1H, d, J = 8.3 Hz), 7.62 (1H, t, J = 7.5
Hz), 7.41 (2H, s), 6.81 (1H, d, J = 8.7 Hz), 3.98 (2H, t, J = 7.1 Hz), 1.55 (2H, m, J = 7.4 Hz),
1.30 (2H, m, J = 7.4 Hz), and 0.89 (3H, t, J = 7.3 Hz).

13

C-NMR (DMSO-d 6 , 100 MHz):

δ 164.2, 163.4, 153.1, 134.4, 131.4, 130.1, 129.7, 124.4, 122.3, 119.8, 108.6, 108.0, 30.3, 20.3,
14.2. ESI-MS: for C 16 H16 N 2 O 12 : calculated m/z = 291.1104 [M + Na]+; observed m/z =
291.1111 [M + Na]+; 2.4 ppm error.
3.2.4

tert-Butyl-2-hydroxyethyl(methyl)carbamate Synthesis
N-(methylamino)ethanol 3 (4.41 g, 55.1 mmol) was dissolved in dry THF under nitrogen

atmosphere and chilled using an ice bath. Di-tert-butyl dicarbonate (35.8 mL of a 2 M solution
in THF, 71.7 mmol) was added slowly to the reaction mixture and left to stir for 2 hours. The
solvent was removed under vacuum and the crude product was purified using silica gel
chromatography (1:1 Hexanes:EtOAc, Rf = 0.37).

Product was collected and after a night on

high vacuum afforded 4 as a slight yellow to colorless oil (6.67 g, 69%).

1

H-NMR (CDCl3 , 400

MHz): δ 3.63 (2H, t, J = 5.6 Hz), 3.27 (2H, t, J = 6.1 Hz), 2.83 (3H, s), 1.36 (9H, s).

13

C-NMR

(CDCl3 , 100 MHz): δ 154.0, 79.6, 60.8, 60.0, 51.1, 35.3, and 28.2. ESI-MS: for C 16 H16 N 2 O 12 :
calculated m/z = 198.1101 [M + H]+; observed m/z = 198.1101 [M + H]+; 0.0 ppm error.
3.2.5

NN Synthesis
To a dry round bottom flask under argon atmosphere was added 120 mL dry toluene and

sodium carbonate (4.65 g, 0.044 mol). To the toluene suspension was added phosgene (28.5 mL
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from a 20% solution in toluene, 53.5 mmol) and 100 µL dry DMF, after which the solution was
chilled in an ice bath.

4 (1.9 g, 10.7 mmol) was dissolved in 20 mL dry toluene and slowly

added to the phosgene solution over a 10 minute period.

After 2 hours, nitrogen was rapidly

bubbled through the reaction for 30 minutes to remove excess phosgene.

Reaction was then

filtered and solvent removed under reduced pressure. The colorless oil product was dissolved in
15 mL dry DMF under a nitrogen atmosphere and 2 (0.36 g, 1.34 mmol) was added.
stirring for 20 hours the DMF was removed using a rotary evaporator.

After

Product was partially

purified using silica gel column chromatography (2:1 DCM:EtOAc), leaving a yellow solid after
removal of the solvent.
The partially purified product was dissolved in 15 mL dry DCM under nitrogen
atmosphere to which 10 mL trifluoroacetic acid was added slowly.

After one hour, the solvent

was removed and the product was purified using silica gel column chromatography (1:5
DCM:EtOAc, Rf = 0.22).
1

Removal of the solvent yielded 5 as a yellow solid (0.298 g, 60%).

H-NMR (DMSO-d 6 , 400 MHz): δ 8.70 (1H, d, J = 8.4 Hz), 8.51 (2H, dd, J = 7.4 Hz), 8.17 (1H,

d, J = 8.2 Hz), 7.86 (1H, t, J = 7.5 Hz), 4.44 (2H, t, J = 4.9 Hz), 4.03 (2H, t, J = 7.4 Hz), 3.30
(2H, t, J = 5.2 Hz), 2.65 (3H, s), 1.60 (2H, m, J = 7.6 Hz), 1.33 (2H, m, J = 7.5 Hz), 0.91 (3H, t,
J = 7.4 Hz).

13

C-NMR (DMSO-d 6 , 100 MHz): δ 163.9, 163.4, 158.5, 158.2, 154.2, 140.9, 132.1,

131.5, 129.7, 128.8, 126.9, 124.4, 122.8, 119.2, 119.0, 117.8, 116.2, 61.1, 47.9, 33.4, 31.2, 30.1,
20.3, 14.2. ESI-MS: for C 16 H16 N 2 O 12 : calculated m/z = 370.1761 [M + H]+; observed m/z =
370.1760 [M + H]+; 0.3 ppm error.
3.2.6

Q 1 NN Synthesis
5 (55.2 mg, 0.15 mmol) was dissolved in 4 mL DMF under a nitrogen atmosphere, to

which 60 µL triethylamine was added.

To DMF was added HOBt (41.0 mg, 0.30 mmol) and
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EDCI (58.0 mg, 0.30 mmol), and 6A (33.0 mg, 0.15 mmol).

Reaction was left to stir for 12

hours, after which the solvent was removed under high vacuum.

Product was purified using

silica gel column chromatography (1:1 DCM:EtOAc, Rf = 0.29).
afforded Q 1 NN as a yellow solid (31.8 mg, 37%).

1

Removal of the solvent

H-NMR (DMSO-d 6 , 400 MHz): δ 8.66 (1H,

dd, J = 7.7 Hz), 8.49 – 8.37 (2H, m, J = 8.2 Hz), 8.11 (1H, dd, J = 8.2 Hz), 7.82 (1H, m, J = 9.0
Hz), 4.34 & 4.28 (2H, 2t, J = 5.9 Hz), 4.03 (2H, t, J = 4.2 Hz), 3.63 (2H, t, 5.8 Hz), 3.02 – 2.89
(3H, m), 2.55 (2H, m, J = 8.2 Hz), 2.35 (2H, m, J = 8.4 Hz), 1.90 (5H, m), 1.80 – 1.72 (4H, m),
1.59 (2H, m, J = 8.0 Hz), 1.34 (2H, m, J = 7.7 Hz), and 0.91 (3H, t).

13

C-NMR (DMSO-d 6 , 175

MHz): δ 186.9, 186.6, 186.4, 186.2, 171.4, 171.1, 163.4, 162.9, 154.0, 142.6, 140.7, 140.5,
140.3, 140.1, 139.9, 139.8, 139.7, 131.6, 130.9, 129.4, 128.3, 126.4, 124.0, 122.2, 118.5, 118.3,
117.1, 72.0, 70.1, 62.5, 62.3, 48.2, 46.4, 35.8, 33.1, 31.6, 30.9, 29.7, 22.3, 22.1, 19.8, 13.7, 12.1,
12.0, 11.9, 11.7, and 11.6. ESI-MS: for C 16 H16 N 2 O 12 : calculated m/z = 574.2548 [M + H]+;
observed m/z = 574.2556 [M + H]+; 1.4 ppm error.,
3.2.7

Q 3 NN Synthesis
5 (113 mg, 0.31 mmol) was dissolved in 5 mL DMF under a nitrogen atmosphere, to

which 400 µL triethylamine was added. To DMF was added HOBt (83.8 mg, 0.62 mmol) and
EDCI (118.9 mg, 0.61 mmol), and 6B (77.5 mg, 0.31 mmol). Reaction was left to stir for 12
hours, after which the solvent was removed under high vacuum.
silica gel column chromatography (1:1 DCM:EtOAc, Rf = 0.61).
afforded Q 3 NN as a yellow solid (57.8 mg, 31%).

1

Product was purified using
Removal of the solvent

H-NMR (DMSO-d 6 , 400 MHz): δ 8.68 (1H,

t, J = 9.4 Hz), 8.49 (2H, m, J = 6.6 Hz), 8.14 (1H, m, J = 8.2 Hz), 7.84 (1H, m, J = 5.4 Hz), 4.37
& 4.20 (2H, 2t, J = 5.6 Hz), 4.03 (2H, t, J = 7.3 Hz), 3.66 & 3.54 (2H, 2t, J = 5.3 Hz), 3.05 –
2.80 (5H, m, J = 22.4 Hz), 1.97 (3H, d, J = 5.3 Hz), 1.83 – 1.77 (6H, m, J = 9.8 Hz), 1.60 (2H,
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m, J = 6.5 Hz), 1.35 – 1.29 (8H, m, J = 7.4 Hz), and 0.91 (3H, t).

13

C-NMR (DMSO-d 6 , 175

MHz): δ 190.3, 186.8, 171.9, 171.5, 163.5, 162.9, 155.3, 153.9, 143.2, 140.6, 136.5, 134.6,
131.6, 128.3, 124.0, 122.3, 117.3, 62.5, 46.2, 45.7, 37.3, 37.2, 33.2, 29.7, 27.9, 19.8, 13.7, 12.5,
and 11.6. ESI-MS: for C 16 H16 N 2 O 12 : calculated m/z = 602.2861 [M + H]+; observed m/z =
602.2872 [M + H]+; 1.8 ppm error.
3.2.8

Acetyl-NN Synthesis
5 (63.5 mg, 0.17 mmol) was dissolved in 2 mL dry DMF under a nitrogen atmosphere.

From a 1 M solution in DCM, 0.8 mL acetyl chloride (0.8 mmol) and 0.2 mL triethylamine was
added to the DMF solution.

Reaction was left to stir for 4 hours, after which the solvent was

removed using a rotary evaporator.

Product was purified using silica gel chromatography (1:4

DCM:EtOAc, Rf = 0.13). Solvent was removed and Acetyl-NN collected as a yellow solid (28.4
mg, 40%).

1

H-NMR (DMSO-d 6 , 400 MHz): δ 8.61 (1H, m), 8.49 (2H, m, J = 7.3 Hz), 8.11 (1H,

m, J = 2.6 Hz), 7.83 (1H, m, J = 7.4 Hz), 4.35 – 4.27 (2H, 2t), 4.02 (2H, t, J = 7.3 Hz), 2.63 (2H,
m, J = 12.6 Hz), 3.05 – 2.86 (3H, 2s), 2.04 – 1.99 (3H, 2s), 1.60 (2H, t, J = 7.4 Hz), 1.35 (2H, t, J
= 7.5 Hz), and 0.91 (3H, t, J = 7.6 Hz). ESI-MS: for C 16 H16 N 2 O 12 : calculated m/z = 412.1867
[M + H]+; observed m/z = 412.1872 [M + H]+; 1.2 ppm error.
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Scheme 3.2. Synthesis of Acetyl-NN.
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3.2.9

Cyclic Voltammetry
Cyclic voltammetry was performed on NN and Q 3 PA in dry acetonitrile and 0.1 M

tetrabutylammonium perchlorate.

Princeton applied research potentiostat/galvanostat model

273A was used along with the program Power suite-2.53.

Voltammograms were collected at

room temperature after degassing the solution with nitrogen for 20 minutes.

A glassy-carbon

electrode (pretreated for ten minutes) was used as the working electrode, platinum wire as the
counter electrode, and a silver (Ag/Ag+) reference electrode was used. To obtain the oxidation
peak for NN, the solution was cycled from 0.5 to 2.0 back to 0.5 V at 100 mV/second and the
reduction peak was collected by cycling from 0.0 to -1.8 back to 0.0 V at 100 mV/second.
Quinone reduction and oxidation peaks were determined after cycling from -0.25 to -2.0 back to
-0.25 at 100 mV/second. Afterwards, ferrocenecarboxylic acid was run from 0.0 V to 0.8 V and
back to 0.0 V at 100 mV/second in 0.1 M tetrabutylammonium perchlorate in ACN using a 3.0
M KCl Ag/AgCl reference electrode and again with the Ag/Ag+ electrode. From this, the halfwave potential was determined for both reference electrodes. To convert the E 1/2 to a standard
hydrogen electrode (SHE) value, 0.21 V was added to the E 1/2 value for the Ag/AgCl electrode
sample value.23

The difference between the two reference electrode E 1/2 values was used to

convert all values to SHE.
3.2.10 Enzyme Kinetics
Kinetic

measurements

were

performed

using a

PerkinElmer

LS55

fluorescence

spectrometer. All measurements were collected at room temperature in pH 7.4, 0.1 M PBS with
0.1 M KCl and supplemented with 0.007% BSA while exciting at λ ex = 390 nm and following
the emission at λ em = 470 nm as NN was released following the enzymatic reduction of Q 3 NN.
A stock solution of 100 µM β -nicotinamide adenine dinucleotide, reduced disodium salt (β -
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NADH, Sigma-Aldrich) was made using the PBS buffer and subsequently used to make all other
solutions as to have a final concentration of 100 µM β -NADH in each assay. Solutions of Q 3 NN
were made from the NADH/0.1 M PBS solutions ranging from 2 to 60 µM. A 1.33 µg/mL stock
solution of recombinant human NQO1 (Sigma-Aldrich) was prepared using the same buffer as
above to give 20 µg hNQO1 per assay.

Each assay was performed in a quartz fluorescence

cuvette containing 1.5 mL Q 3 NN solution and initialized by the addition of 1.5 mL hNQO1
solution.

Measurements were collected every 30 seconds for five minutes.

Fluorescence units

were converted to concentration by creating stock solutions of Q 3 NN containing the same
concentration of NN and measuring the fluorescence with no hNQO1 present.

Measurements

were done in triplicate.
3.2.11 Flow Cytometry
Cells were suspended at a count of 1 × 106 in 1 mL of complete growth medium. To each
suspension was added Q 3 NN from a stock DMSO solution to give a final concentration of 20

µM of the sensor, while keeping the DMSO at approximately 1% or less after dilution. The
suspension was incubated with the sensor for 10 or 60 minutes at 37 °C. After which 30 mL of
4% paraformaldehyde (maintained at 37.0 °C) in 0.1 M PBS was added to the mixture to fix the
cells for 1 hour. After fixation, the cells were washed twice with 0.1 M PBS and resuspended in
1 mL PBS.

Data acquisition was carried out on a iCyt Reflection flow cytometer (iCyt,

Champaign, IL) configured for DAPI fluorescence measurements using the 405 nm excitation
laser and a 457/60 nm bandpass filter for emission. Fluorescence measurements were made with
logarithmic amplification.

A total of 10,000 cells per sample were acquired using Winlist

software (Verity Software House, Topshame, ME) and FlowJo software was used to plot the
data.
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3.2.12 Cell Viability
To determine cell viability, a suspension of HT-29, A549 and H596 cells were cultured in
5 mL of their respective complete growth medium in a sterile tube. To the medium was added
Q 3 NN (from a 1.8 mM stock solution) in DMSO, to give a 20 µM Q 3 NN solution and the cells
were incubated at 37 °C, 5% CO 2 for 60 minutes, after which 1 mL of the suspension was
removed and 0.1 mL trypan blue was added.

Cells were immediately counted using a

hemocytometer with the aid of a microscope. The remainder of the 4 mL of suspended cells was
left in the incubator for 24 hours. Cells were again removed and counted as above.
3.2.13 Optical Differentiation
HT-29, A549, and H596 cells were grown overnight on 22 x 22 mm glass cover slips in
complete growth medium. Old growth medium was removed and replaced with a 20 µM Q 3 NN
solution in fresh growth medium. Cells were incubated at 37 °C with the sensor for 10 minutes
and then rinsed with 0.1 M PBS. Cover slips of each cell line were immediately placed upside
down on glass slides and visualized with a Mineralight Model UVGL-25 (365 nm, 0.16 amps,
~60 Hz). Image was taken using a Kodak digital camera.
3.2.14 Widefield Fluorescence Imaging of Fixed Cells
The images were acquired using a Leica DM RXA2 fluorescent microscope equipped
with a 100x 1.4NA objective lens and a Cooke SensiCam QE. Slidebook software was used to
control the camera and microscope as well as image renormalization, deconvolution and scale
bar placement. The nucleus was stained with DRAQ5 and a Leica CY5 filter set (λ ex 620/60, λ em
700/75) was used when visualizing this dye.

NN dye was visualized using a Leica A4 filter set

(λ ex 360/40 λ em 470/40). HT-29, A549, and H596 cells were grown overnight on 22 x 22 mm
glass cover slips in 6 well plates in their respective complete culture medium at 37 °C in 5%
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CO 2 . Prior to sensor addition the old growth medium was replaced with 2 mL of fresh medium
maintained at 37 °C. A 1.87 mM solution of Q 3 NN was made in DMSO and 21.4 µL was added
to each well to give a 20 µM solution of the sensor. The cells were incubated with the Q 3 NN in
the 37 °C incubator for 10 minutes, after which the cover slips were removed and rinsed with pH
7.4, 0.1 M PBS. Cells were immediately fixed with 4% paraformaldehyde in pH 7.4, 0.1 M PBS
for 30 minutes.

After fixation, the cover slips were again rinsed with buffer and then submerged

in a 3 µM DRAQ5 solution in 0.1 M PBS for 5 minutes. After staining, the cover slips were
rinsed with buffer and mounted to glass slides using immu mount.

Glass slides were left in the

dark overnight to allow the immu mount to dry, after which the cells were imaged.

Image

analysis was performed in ImageJ.
3.2.15 Confocal Colocalization
Confocal fluorescence images were acquired with a Leica TCS SP5 tandem scanning
multiphoton laser scanning microscope at the Cell Biology and Bioimaging Core within
Pennington Biomedical Research Center

at

Louisiana

State

University,

Baton Rouge.

Experiments were performed using a 40x oil immersion objective lens (1.25 NA).

Imaging of

the lysotracker and Q 3 NN loaded HT-29 cells was accomplished using a sequential scanning
method with sensor excitation via a 405 nm laser at 10% output and collecting emitted light
between 417-467 nm.

Lysotracker Red was excited using a 561 nm laser at 10% output and

emitted light collected between 574-621 nm. DIC images were collected using a PMT detector
and 633 nm light at 3% output as an illumination source. All imaging was done at 37 °C using
the Leica TCS SP5 in resonant scanning mode and collecting images bidirectionally (16 KHz) at
a zoom setting of 3.6.

Images were line averaged 64 times.

HT-29 cells were incubated

overnight in black 35 x 10 mm, 22 mm well glass bottom dishes (Chemglass Life Sciences) in its
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complete growth medium at 37 °C with 5% CO 2 .

Prior to imaging, the medium was removed

and replaced with F-12K medium (containing no phenol red) maintained 37 °C.

From a

concentrated solution of Q 3 NN in DMSO, the sensor was added directly to the dish to give a
concentration of 20 µM (while ensuring approximately 1% or less DMSO with respect to
medium). Cells were incubated with Q 3 NN for a total time of 20 minutes. Five minutes prior to
imaging, Lysotracker Red-DND 99 was added from a stock solution in DMSO to give a
concentration of 0.1 µM.
3.2.16 In vitro 2-Photon Imaging
2-photon confocal fluorescence images were acquired with a Leica TCS SP5 tandem
scanning multiphoton laser scanning microscope at the Cell Biology and Bioimaging Core within
Pennington Biomedical Research Center

at

Louisiana

State

University,

Baton Rouge.

Experiments were performed using a 40x oil immersion objective lens (1.25 NA).

Imaging of

live cells was accomplished using a MaiTai two-photon laser tuned to 750 nm (3% laser power,
modelocked Ti:sapphire laser; Tsunami Spectra Physics) and emission was collected using a
short-pass 680 nm filter. DIC images were collected using a PMT detector and 633 nm light at
3% output as an illumination source. All imaging was done at 37 °C using the Leica TCS SP5 in
resonant scanning mode and collecting images bidirectionally (16 KHz) at a zoom setting of 3.6.
Images were line averaged 64 times.

HT-29, A549, H596, and H446 cells were incubated

overnight in black 35 x 10 mm, 22 mm well glass bottom dishes (Chemglass Life Sciences) in
their respective complete growth medium at 37 °C with 5% CO 2 . Prior to imaging, the medium
was removed and replaced with F-12K medium (containing no phenol red) maintained at 37 °C.
From a concentrated solution of Q 3 NN in DMSO, the sensor was added directly to the dish to
give a concentration of 20 µM (while ensuring approximately 1% or less DMSO with respect to

100

medium).

Cells were then imaged, with no washing or medium removal steps, after 10 minutes

of incubation with Q 3 NN. Image analysis was performed in ImageJ.
3.3

Results and Discussion

3.3.1

Thermodynamic Analysis for PeT Quenching
The sensor Q 3 NN is of a fluorophore-linker-trigger format with a naphthalimide dye as

the fluorophore, which has been shown to have its fluorescence modulated by PeT.14

Scheme

3.1 shows the synthesis of Q 3 NN and Q 1 NN. The sensor utilizes a PeT quenching mechanism
with a quinone as the trigger moiety that would not only act as an electron acceptor, but also as
an electron donor when in the reduced hydroquinone state (Figure 3.2). When the naphthalimide
is excited, the sensor undergoes oxidative electron transfer (OeT), with the excited electron in the
fluorophore transferring to the electron poor quinone, thus quenching the fluorescence. After the
quinone undergoes two-electron reduction to hydroquinone, the system is quenched via reductive
electron transfer (ReT) by electron donation from the hydroquinone to the empty ground state in
the dye.

The fluorescence is finally revealed after cleavage of the hydroquinone unit (through

lactonization).

OeT

ReT

Φ = 0.07

Φ = 0.23

Figure 3.2. Schematic representation of the unique utilization of PeT in the hNQO1 sensor
Proposed quenching mechanisms for Q 3 NN prior (OeT) and post (ReT)
Q 3 NN.
chemical/enzyme catalyzed reduction, and the subsequent release of the fluorescent NN dye.
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This system would create a highly specific sensor towards the two electron reduction by
hNQO1 and only reveal its fluorescence after the removal of the quinone subunit from the parent
dye.

This will not only produce a large fluorescence enhancement (FE), but also ensures

minimal background signal from the quenched probe.
naphthalimide-butyl

fluorophore

fluorescence in aqueous media.

due

14, 24

to

its

The base dye chosen was a 1,8-

versatility,

biological

inertness,

and

large

Quinone propionic acid, which can be reduced via chemical

or enzymatic catalyzed reactions, was chosen as the trigger group for its ability to react as an
electron acceptor/donor (hydroquinone form) in the PeT quenching process, stability against
biological reductants, and reactivity towards hNQO1.22,

25-27

The quinone contains three methyls

in the “trimethyl-lock” positions as to create a rapid and spontaneous release from the probe
allowing for real-time detection of hNQO1.28
Given the nature of the fluorescence enhancement mechanism, reductive-removal of the
trigger

group,

the

Rehm-Weller

equation

was

used

to

determine if quenching was

thermodynamically possible prior to and post reduction by ensuring a sufficiently negative
energy change for PeT (∆G PeT ) until cleavage of the trigger group occurs, Equation 3.1.29
𝑒2

∆G𝑃𝑒𝑇 = 𝐸𝑜𝑥 − 𝐸𝑟𝑒𝑑 − ∆𝐺00 − 𝜀𝑑

Equation 3.1

In this equation, E ox is the oxidation potential of the donor, E red is the reduction potential
on the acceptor, ∆𝐺00 is the energy of the first excited singlet state, and

interaction energy of the ion pair.

𝑒2

𝜀𝑑

is the Coulombic

To ensure complete quenching, the quinone was attached to

the naphthalimide via a short N-methylethanolamine linker through a carbamate bond on the
naphthalimide ring.

This linker provides three crucial properties: it creates a tertiary amide at the
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quinone end which prevents the formation of a non-activatable spirolactam, shifts the
fluorescence of the dye in a hypsochromic shift increasing the energy of the first excited singlet
state (decreasing ∆G PeT ), and is sufficiently short to allow for a high probability of electron
transfer.24,

30
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Figure 3.3. Intersection of the normalized absorbance spectrum of NN and its fluorescence
spectrum; used to calculate the energy of the ground state to the fist excited state. Spectra were
obtained in acetonitrile as the solvent.
The energy of the first excited singlet state of NN was measured to be 3.06 eV, by
determining the interception of the normalized absorbance and fluorescence spectra (Figure 3.3),
and the Coulombic interaction variable is known to be 0.06 eV.29

In the first quenching step,

prior to quinone reduction, oxidative electron transfer (OeT) takes place by the transfer of the
excited electron to quinone.

Using cyclic voltammetry (CV), the oxidation potential of NN

(Figure 3.4) was measured as E p,a = 1.75 eV vs SHE and the reduction potential for the quinone
was E p,c = -1.02 eV vs SHE (Figure 3.5). This generates -0.35 eV as ∆G PeT , which leads to the
thermodynamic possibility of electron transfer from the excited dye to the electron poor quinone.
Post quinone reduction, the quenching system switches to a reductive electron transfer (ReT)
mechanism.

Again using CV, the reduction potential of NN (Figure 3.4) is E p,c = -1.33 eV vs
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SHE and the oxidation potential for the 2-electron reduced quinone species (Figure 3.5) is
E p,c = -0.9 eV vs SHE, also giving a sufficiently negative ∆G PeT in -2.69 eV.
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Figure 3.4. Cyclic voltammograms of NN showing the oxidation and reduction peaks used to
calculate ∆G PeT . Potential scans were conducted in a 0.1 M tetrabutylammonium perchlorate
solution in acetonitrile.
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Figure 3.5. Cyclic voltammogram of Q 3 PA showing the oxidation and reduction peaks used to
calculate ∆G PeT . Potential scans were conducted in a 0.1 M tetrabutylammonium perchlorate
solution in acetonitrile.
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3.3.2

Reduction Produces Dequenching of Q 3 NN
The absorbance spectroscopy for Q 3 NN and NN was found to be broad, ranging from

310 to 430 nm centered at 374 nm, Figure 3.6.

As shown in Figure 3.7, fluorescence

spectroscopy of 2 µM solutions of Q 3 NN and NN displayed spectra ranging from 420 to 610 nm
and containing a large Stokes shift of 116 nm, producing minimal overlap with its absorbance
spectrum. Using quinine sulfate as a standard (Φ = 0.54),31 quantum yields for Q 3 NN and NN
were obtained in aqueous media at physiological pH (0.1 M phosphate-buffered saline, PBS, pH
= 7.4) and were calculated at 0.007 and 0.23 (33-fold FE), respectively.
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Figure 3.6. Absorbance spectra of 20 µM Q 3 NN, NN, and Acetyl-NN in pH 7.4, 0.1 M PBS
with 0.1 M KCl.
Quantum yield was determined using Equation 2.1. The quantum yield for NN is
comparable to other sensors applied to cancer detection and localization that have yields ranging
from 0.0028 for indocyanine green to 0.21 for Cy5.5 dyes.6, 32 As proof positive that NN could
indeed be released after quinone reduction, a strong reducing agent (sodium dithionite) was
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added to a 10 µM solution of Q 3 NN, Figure 3.8. While exciting the solution at 370 nm and
following the emission intensity at 470 nm, it was found that NN was rapidly released postreduction.
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Figure 3.7. Fluorescence spectra of 2 µM solution of Q 3 NN and NN in pH 7.4, 0.1 M PBS with
0.1 M KCl. λ ex = 378 nm.
As method of checking the 2-step PeT mechanism, a second probe was synthesized
(Q 1 NN) where the quinone was lacking the two geminal methyls of the trimethyl-lock, thus
significantly reducing cyclization and dye release.22

As seen in Figure 3.8, Q 3 NN undergoes a

much more rapid dye release after the addition of sodium dithionite when compared to that of
Q 1 NN.

Combining the very unique quenching mechanism, large Stokes shift, pronounced

fluorescence signal enhancement, practicality of an off-on type sensor, and the biologically
stable trigger-group, Q 3 NN can then be utilized as an hNQO1 sensor in real-time applications
such as flow cytometry and fluorescence imaging.

106

1000
N

O

O

Fluorescence (RFU)

800

O

Q3 NN
HN

O

N

O

O
O

O

600
Na2 S2 O4
addition

400

O

N

O

Q1 NN
HN

200

O
O

N

O

O
O

O

0
0

10

20

30

40

200 300 400 500 600

Time (Minutes)
Figure 3.8. Comparing the release of NN in 10 µM solutions of Q 3 NN and Q 1 NN in pH 7.4, 0.1
M PBS following reduction via addition of 2.75 mg sodium dithionite into cuvettes. Solutions
were excited at λ ex = 370 nm and emission followed at λ em = 470 nm.
3.3.3

Acetyl-NN and Other NN Properties
To ensure the amide bond connecting the linker and quinone did not significantly

influence the optical properties of NN and Q 3 NN, Acetyl-NN was synthesized (Scheme 3.2).
Absorbance and fluorescence properties of Acetyl-NN were determined and then compared to
NN and Q 3 NN.

The absorbance spectrum for 20 µM Acetyl-NN (Figure 3.6) had a similar

maximum to that of NN, but appeared to have a higher extinction coefficient.

Using Equation

2.1 and NN as the standard, the quantum yield for Acetyl-NN was calculated to be Φ = 0.35.
Comparing the fluorescence spectra for NN, Q 3 NN, and Acetyl-NN in pH 7.4, 0.1 M PBS
demonstrates the increase in quantum yield for each compound while exciting at 365 nm, Figure
3.9.
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Figure 3.9. Fluorescence spectra of Q 3 NN, NN, and Acetyl-NN in pH 7.4, 0.1 M PBS (each
solution had an absorbance of 0.048 abs.). λ ex = 365 nm.
As detailed in Chapter 2, one of the issues with the Q 3 -Rho-Morph sensor was the
quenching of the Rho-Morph product dye by NADH.
naphthalimide dye scaffold.

This was an issue solved by using the

It was found that after one hour of mixing Rho-Morph into a 100

µM solution of NADH, the fluorescence of the dye was reduced by 26%. On the other hand, NN
fluorescence was only reduced 4% while in the presence of NADH, Figure 3.10.

Stability of

Q 3 NN at low pH was also tested to ensure no non-specific activation if the sensor accumulated
in acidic compartments in cells.

A 5.0 µM Q 3 NN solution in 0.1 M PBS had its fluorescence

spectrum observed every 10 minutes at a pH of 5.0 over a 50 minute period while exciting at λ =
380 nm, Figure 3.11. It was found that Q 3 NN was relatively stable at a low pH and would be
suitable for cellular imaging, even after longer incubation periods.
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Figure 3.10. Observing the fluorescence of 2.0 µM NN in 0.1 M PBS pH 7.4 while in the
presence of 100 µM NADH. λ ex = 380 nm and λ em = 470 nm.
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Figure 3.11. Fluorescence spectra of 5 µM Q 3 NN in 0.1 M PBS at pH 5.0 over a 50 minute
period. Scans were taken every 10 minutes while exciting at λ = 380 nm.
As seen with other amine-linker-naphthalimide dye systems, the fluorescence in NN is
also PeT modulated by the pKa of the secondary amine at the end of the linker.33-36 For this PeT
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quenching system, the neutral secondary amine acts as an electron acceptor, quenching the
naphthalimide dye.

It was found that the pKa of NN was approximately 12.0, sufficiently high

enough that physiological pH would have little effect on intensities for cellular imaging
purposes, Figure 3.12.
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Figure 3.12. Fluorescence intensities of NN with respect to change in pH, λ ex = 385 nm and λ em
= 480 nm.

3.3.4

Enzyme Kinetic Analysis With hNQO1
To confirm that Q 3 NN was a suitable substrate for hNQO1 and to ensure the rate of

release of the fluorophore in the presence of the enzyme, we measured the apparent kinetic
activity of the enzyme relative to dye release.

As shown in Figure 3.13, results displayed as

Michaelis-Menten kinetics with K m = 3.86 ± 0.79 µM, V max = 0.037 ± 0.002 µmol min-1
mg·NQO1-1 , k cat = 0.019 ± 0.001 sec-1 , and k cat /K m = 4.9 (± 1.0) × 103 M-1 sec-1 . Due to the
single activation mechanism and the non-bulky linker, the kinetic constants are significantly
higher than our reported hNQO1 activatable fluorophore (Q 3 -Rho-Morph), Chapter 2.25
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This

higher enzymatic affinity and rapid dye release ensures sufficient signal enhancement for rapidly
detecting hNQO1.
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Figure 3.13. Michaelis-Menten kinetics plot of hNQO1 (20 µg) towards Q 3 NN. Inset contains
sample 1 µM Q 3 NN assay observing NN release by fluorescence, relative to fluorescence signal
of total release (1 µM NN).
3.3.5

Rapid Differentiation Between Target Cells
I next wanted to assess the ability to rapidly differentiate between cell lines known to

contain hNQO1 and those devoid of the enzyme with and without the aid of instrumentation.
The colorectal carcinoma cell line HT-29 and the non-small cell lung cancer (NSCLC) cell line
A549 were both previously shown to contain hNQO1 activity and the NSCLC H596 is found to
be devoid of hNQO1.17,

37

Using cell lines originating from different organs demonstrates the

breadth at which the probe can accurately detect hNQO1 in cells from varying locations. After a
ten minute incubation period in a solution containing Q 3 NN, it was possible to differentiate
between the cells using only a fluorescent lamp emitting at 365 nm and the un-aided eye, Figure
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3.14. Both HT-29 and A549 appeared fluorescent blue and the cell line H596 was found to emit
no fluorescence. The ability to visually determine the presence of hNQO1 in cells is again due to
the marked difference in fluorescence from the quenched Q 3 NN and unquenched NN, the high
quantum yield of NN, and the appearance of the fluorescence in the visual spectrum.

This

technique helps demonstrate the simplicity of the sensor as it comes to the rapid detection of
tumor cells.

Given the ability to visually detect tumor cells and determine accurate

tumor/healthy tissue borders in real-time, without the aid of imaging equipment, would be highly
beneficial for surgical resection of tumors with small foci.

Figure 3.14. Optical differentiation between HT-29 (A), A549 (B), and H596 (C) cells after
incubation with Q 3 NN. Fluorophore is excited by a handheld lamp emitting 365-nm light.
Similarly, flow cytometry assays were used to assess the applicability of Q 3 NN to rapidly
detect hNQO1 in tumor cells.

The probe was incubated in a suspension of HT-29, A549, and

H596 cells for 10 or 60 minutes and a flow cytometer was used to detect the fluorescence in
individual cells.

In Figure 3.15 is depicted the fluorescence signal intensities per cells of each

cell line in relation to the activation of Q 3 NN. The results showed high intensity unimodal
fluorescence signal from Q 3 NN activation in HT-29/A549, while the negative cell line, H596,
produced minimal fluorescence.

It was also found that there was little to no increase in signal
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when increasing the incubation time from ten to sixty minutes, demonstrating the rapid and
substantial activation in A549/HT-29 and the stability Q 3 NN in H596, Figure 3.15. With the low
fluorescence in the H596 cells and no increase in signal over a longer incubation period, the
results demonstrate lack of non-specific activation of Q 3 NN.

Given the stability and the very

short incubation time to reveal sufficient fluorescence signal to differentiate between cells
absent/containing hNQO1, it is indicated that Q 3 NN is a highly sensitive and selective sensor
and can be used as a rapid tumor cell detection sensor.

B

A

Figure 3.15. Flow cytometry assay of Q 3 NN activation in 2 hNQO1-containing cell lines (A549
and HT-29) and a cell line with no hNQO1 activity (H596) after a 10 minute incubation period
(A) or a 60 minute incubation period (B). Assay was performed by counting 10,000 cells and the
concentration of Q 3 NN was 20 µM.
3.3.6

Q 3 NN for the Specific Detection of hNQO1 Overexpressing Cells
With the positive results from enzyme kinetics and flow cytometry, I sought to use a

complimentary technique in fluorescence microscopy to further validate the effectiveness of
Q 3 NN to rapidly distinguish cells with hNQO1 activity and provide spatial resolution on the
activation and compartmentalization of the NN dye released.

In agreement with flow cytometry

data, fluorescence microscopy on fixed cells and a ten minute incubation time also revealed
significant sensor uptake and activation leading to intracellular fluorescence for the A549 and
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HT-29 cell lines and minimal signal for H596, Figure 3.16. The average cytosolic signal was 9
times higher in A549 cells compared to H596, while the average intensities were 23 times higher
in HT-29 compared to H596.

Values of 9- to 23-fold increase from target cells to non-target

cells is substantially higher than 2.5-fold increase, which previously was considered to be
substantial accumulation.38

Though the NN is excited near the ultraviolet region which can

produce significant absorbance from hemoglobin and background fluorescence, the activation of
Q 3 NN to NN yields high signal-to-background relative to other exogenously introduced sensors
ensuring sensitive tumor analysis.15

From these results, it appears that paraformaldehyde

fixation has little effect on dye quantum yield and also that there is no efflux of the dye from the
fixed cells.

Being able to retain its fluorescence after fixation gives it the potential to be

invaluable for ex vivo quantitative analysis of excised tumors for a period of time after surgical
removal.

Figure 3.16. Widefield fluorescent imaging of fixed HT-29 (A,D), A549 (B,E), and H596 (C,F)
cells after a 10 minute incubation with Q 3 NN. Top row contains images of NN production (blue)
and the bottom row is the overlays with the nuclei (red). Scale bars are 10 µm.
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To determine the fate of the fluorophore NN after intracellular activation, confocal
microscopy was used to localize NN in lysosomes using Lysotracker Red as an organellespecific probe.

For these experiments, live HT-29 cells were used after incubating for 20

minutes with Q 3 NN, to which Lysotracker Red was added to the media in the imaging dish. It
was found that a majority of the NN signal originated from the cytosol, while accumulation did
occur in late endosomes/lysosomes, Figure 3.17. This was an expected fate for intracellular NN
due to the ionizable amine at the end of the linker, because it is common for amine containing
species to accumulate in acidic vesicles due to the pH difference with the cytosol.

This

accumulation of dye in late endosomes/lysosomes is beneficial in that it leads to slower efflux of
NN and longer intracellular accumulation time, which can further lead to higher signal-tobackground.

Figure 3.17. Confocal image of HT-29 cells depicting the accumulation of NN (A) in lysosomes
(B) after intracellular production. DIC image is also provided for reference (C). Scale bars are
25 µm. Arrows points to localization of NN in lysosomes.
One of the more recent and powerful biologically relevant imaging techniques is
multiphoton microscopy (MP) where fluorophores are excited by two, sometimes even three,
photons at a much lower energy wavelength.39 This system is more advantageous when
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compared to traditional fluorescence microscopy in that longer wavelength photons have a lower
probability of being scattered and can penetrate deeper into tissues, is less phototoxic to tissues,
produces less background

noise due to

less out-of-focus excitation, and yields less

photobleaching of the fluorophores allowing for longer imaging periods.

MP imaging is ideal

for ex vivo thick specimen sampling and in vivo experiments directly observing targets in their
physiological environment where 2D and 3D maps can be generated.6
After incubating in complete growth medium containing Q 3 NN, 2-photon microscopy
revealed significant fluorescence signal enhancement in live HT-29 and A549 cells and minimal
signal in two hNQO1-negative cell lines, H596 and H446 (a small cell lung carcinoma known to
be devoid of hNQO1 activity), Figure 3.18.37

It was calculated that the average cytosolic

fluorescence signal was 13-fold higher in A549 compared to H596 and 3.66 × 104 -fold higher in
H446 cells.

Similar results were obtained with the HT-29 cell line, with the cytosolic intensity

being 15-fold higher compared to H596 and a 4.51 × 104 increase compared to H446. As before,
the signal appears slightly heterogeneous throughout the cytosol with accumulation in small
punctate organelles.

To ensure prolonged exposure to Q 3 NN and NN had little effect on cell

health, cells were incubated in a 20 µM Q 3 NN solution in complete growth medium for one hour
and one day, after which a trypan blue assay was used to determine cell viability.

After one

hour, cell viability for HT-29, A549, and H596 was 97.7%, 98.8%, and 100%, respectively, and
97.7%, 98.7%, and 98.4%, respectively, after one day. Of note, due to the background-to-signal
ratio, this assay requires no time consuming washing step as with “always-on” sensors.

This is

one of the more important aspects of the off-on nature of Q 3 NN in that it significantly reduces
the time between dye addition to detection producing a sensor ideal for a “real-time” detection
technique.
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Figure 3.18. 2-Photon confocal microscopy imaging of live HT-29 (A,E), A549 (B,F), H596
(C,G), and H446 (D,H) cells following a 10 minute incubation time with Q 3 NN. Fluorescence
images of each cell line are on the top row with their respective differential interference contrast
(DIC) image on the bottom row. Images were acquired while exciting at λ ex = 750 nm (3% laser
power) without any washing steps between sensor addition and imaging.
3.3.7

Quantitative Analysis of hNQO1 Probes
The rate of lactonization for Q 3 -Rho-Morph and Q 3 NN after reduction was determined to

give a better understanding of the activation kinetics.

This will provide valuable insight into

future probe design to achieve the most effective probe possible.

In the presence of excess

sodium dithionite the quinone units in Q 3 -Rho-Morph and Q 3 NN should undergo near
instantaneous reduction to the hydroquinone (less than 1 s for Q 3 propionic acid)40 , followed by
the slow step of lactonization of the hydroquinone with concurrent release of the dye. Due the
rapid reduction step, the dye release was considered to be a pseudo-first-order step.

To

determine the rate constant (k) for dye release, Equation 3.2 was used.
[A ]

ln �[A] 𝑡 � = −𝑘𝑡
0

Equation 3.2

In this equation, [A] t and [A] 0 are the concentrations of the reduced probe at time t and
time 0, respectively.

An approximate rate constant for each probe was determine by adding
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excess sodium dithionite to a dilute solution (5 µM) of probe in pH 7.4 0.1 M PBS with 0.1M
KCl and following the fluorescence increase over a long period of time. The rate constant was
calculated by taking the time at which half the maximum signal was achieved and recognizing
that at this point [A] t /[A] 0 = 0.5. For Q 3 NN, the time was 54 minutes for 50% consumption of
Q3NN, yielding a rate constant of k = 2.1 × 10–4 sec–1 . For Q 3 -Rho-Morph, the time was 2.5
minutes resulting in a rate constant of k = 4.62 x 10–3 sec–1 . This shows that Q 3 -Rho-Morph
undergoes dye significantly faster than Q 3 NN, with the rate constant is only 20-fold higher. This
increase in lactonization for Q 3 -Rho-Mrph could be due to the electronic effect of the attached
dye on the amide and the lack of the methyl on the nitrogen in the amide versus Q 3 NN. The
latter is supported in studies by Iresha Perera in the McCarley Group, as it was found that the
Q 3 PA derivative of N-methyl-ethanolamine cyclized at least two times slower than the
ethanolamine derivative in D 2 O) medium.41
A second experiment was also used to highlight the effect the lactonization rate has on
dye release, in which enzyme kinetics were again performed on Q 3 -Rho-Morph where the
oxidation of NADH to NAD+ was followed over time instead of following the formation of RhoMorph.

Due to absorbance overlap at 340 nm this experiment was not possible for Q 3 NN.

Kinetics was performed exactly as written in Chapter 2, except the fluorescence change observed
was from the fluorescent NADH to the nonfluorescent NAD+.

Here, NADH was excited at

340 nm and the emission was observed at 460 nm. The results are displayed in Figure 3.19.
From this, it was found that K m = 5.37 ± 0.67 µM, V max = 0.019 ± 0.001 µmol min-1
mg·NQO1-1 , k cat = 0.01 ± 0.001 sec-1 , and k cat /K m = 1.8 (± 0.4) × 103 M-1 sec-1 . When compared
to the assay in Chapter 2 where the formation of Rho-Morph was followed, the V max for this
NADH fluorescence assay was 9-fold higher. This outcome is as expected due to the two-step
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process of NQO1 reduction then hydroquinone lactonization to yield the free Rho-Morph.

At

this stage, I do not have any direct evidence that would indicate more/less rapid reduction of
Q 3 NN by NQO1 (due to the spectral overlap of the NADH and NN species). However, it is
clear from the dithionite reduction results discussed above that the cyclization process is slower
for Q 3 NN vesus Q 3 -Rho-Morph, and this is probably the major contributor to the somewhat
expected slow V max value for its NQO1 activation (reduction and cyclization).

Future studies

should target enzyme parameters for the NQO1 activation of Q 3 PA linked directly to the
aromatic amine of the naphthalimide or a Q 3 NN-like derivative having a naphthalimide
absorption/emission that is significantly shifted from that of NADH so that the reduction
cyclization steps can be separated, as was possible with the Q 3 -Rho-Morph.
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Figure 3.19. Kinetic plot for recombinant human NQO1 (1 × 10-5 g) towards Q 3 -Rho-Morph in
pH 7.4, 0.1 M PBS, and 0.007% bovine serum albumin while observing the oxidation of NADH.
Solid blue line indicates best fit to Michaelis–Menten equation.
3.4

Conclusions
I have developed a first-generation sensor utilizing a unique use of PeT quenching for use

as an off-on sensor for the rapid, sensitive, and specific detection of hNQO1-containing tumor
cells.

Following activation of the non-fluorescent capped Q 3 NN, the highly fluorescent NN dye

is released leading to high signal-to-background ratios with respect to non-targeted cells. Given
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the enzymatic efficiency of Q 3 NN and the rapid single step activation mechanism postreduction, Q 3 NN was found to be a better substrate for hNQO1 when compared to other
rhodamine-containing sensors and also sensors that require a slow linker cyclization step to
dequench the fluorophore.25,

42-43

Flow cytometry analysis revealed Q 3 NN to be highly specific

and sensitive for tumor cells containing hNQO1 after a short incubation period with the sensor,
allowing for easy differentiation between targeted and non-targeted cells.

Q 3 NN and NN were

found to be biologically compatible to where they were not detrimental to cell health. Confocal
microscopy revealed NN to be found mostly in the cytosol with partial accumulation in acidic
vesicles.

The fluorophore NN was found to be easily excited via a multiphoton laser which is

becoming an increasingly useful medical diagnostic tool given the lower background signal
multiphoton microcopy generates along with the deeper sample penetration, lower phototoxicity,
and less photobleaching.

Given the need for real-time analysis of tumor/healthy tissue, Q 3 NN

has the potential to aid in ex vivo analysis and in vivo detection and resection of tumors of
varying origin.

This is thanks in part to the accumulation in acidic cellular organelles, high

background-to-signal ratio, specificity to hNQO1 leading to high sensitivity to tumor cells, and
stability.
3.5
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CHAPTER 4
SOLVENT DEPENDENCE EFFECTS ON HUMAN NAD(P)H:QUINONE
OXIDOREDUCTASE-1 ACTIVITY
4.1

Introduction
With the growing number of NQO1 substrates and inhibitors for cancer treatment,1-7

there is a pressing need for consistency when determining substrate specificity allowing for more
accurate comparison between substrates.

The most common way to compare substrate

specificity for enzymes is to determine and compare kinetic parameters such as: the theoretical
maximum velocity (V max ), Michaelis constant (K m ), catalytic turnover (k cat ), and catalytic
efficiency (k cat /K m ).8

This is accomplished by performing enzyme assays in very similar

environments, such as in specific buffers, buffer and salt concentrations, pH, same enzyme
activators (such as fetal bovine serum), etc. One of the issues in the execution of enzyme assays
is that a majority of substrates are not highly water soluble, while the native environment of
enzymes is aqueous media.8

To circumvent this problem, solutes are generally dissolved in

organic solvents that are miscible with water.

This inherently imparts a new variable in

determining the ability of an enzyme to catalyze a specific reaction.

As enzymes are intricate

machinery whose nature is to catalyze reactions in specific environments, any perturbation to
that environment can cause drastic changes in enzyme structure and catalytic activity. One of the
largest effects organic solvents have on enzymes is the removal of water from the hydration shell
or the active site in the enzyme causing drastic changes in the solvation of the enzyme.

9-13

This

removal of water leads to denaturation of the 3D structure of the enzyme. These forces include:
hydrogen bonding, van der Waals, and hydrophobic interactions.9

By altering this balance of

forces, a change is created in the enzyme rigidity and the ability to catalyze its specific reaction.
From previous work, it has been found that polar solvents have the ability to penetrate deeper
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into an enzyme, whereas nonpolar solvents have a more limited penetration.9

Along with

polarity, solvents with lower dielectric constants impart stronger electrostatic interactions leading
to more rigid enzymes.11,

14

NQO1 utilizes a flavin adenine dinucleotide (FAD) cofactor in the

active site to catalyze its 2-electron reduction reactions. Faig et al. elucidated the structure of the
FAD unit in the active site of human-NQO1 (hNQO1) and were able to reveal the hydrogen
bonding, van der Waals interactions, and the water molecules between FAD and the hNQO1
protein, Figure 4.1.15

Figure 4.1. Hydrogen bonding and van der Waals interaction observed between FAD and
protein in hNQO1. Open radiated circles indicate hydrophobic interactions. Hydrogen bonds are
represented by dashed green lines; water molecules are shown as blue filled circles.15
As seen in Figure 4.1, there are multiple interactions which are a part of the FAD and
NQO1 protein where the catalysis occurs.

Perturbation of this substructure, and also the

solvation of the enzyme, has the potential to cause drastic fluctuations in enzymes ability to
catalyze the reduction of quinones.
soluble in organic solvents.

As mentioned above, many enzyme substrates are only

This introduction of non-native species to the NQO1 assay

environment can produce inconsistent results in substrate analysis.

Previous work on producing

NQO1 substrates and determining the ability of NQO1 to reduce these compounds has produced
a variety of assay conditions in which different organic solvents are used at low concentrations
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ranging from 0.5% to 2%, or even unspecified amounts.2,
catalyze

the

reduction

of

4-5, 16-19

Here, the ability of hNQO1 to

3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-

dimethylpropionic acid (Q 3 PA) to its hydroquinone under various solvent-buffer systems is
analyzed, Scheme 4.1.
variable, the solvent.

To test hNQO1 activity, multiple assays were performed with only one
The solvents tested are the most commonly used water miscible organic

solvents used in hNQO1 assays: acetonitrile (ACN), ethanol (EtOH), and dimethyl sulfoxide
(DMSO).

By changing only the solvent type and the overall solvent percentage, it will be

possible to elucidate the effect of different organic solvents on the ability of hNQO1 to catalyze
the reduction of quinones.
NADH

O

NAD+

hNQO1O

O

O

hNQO1R

OH

OH

Reduction

O
OH

Lactonization

O

O

OH

OH

Q3PA

Hydroquinone

Lactone

Scheme 4.1. Reduction and lactonization of Q 3 PA by NQO1.
4.2

Experimental Section

4.2.1

Materials and Methods
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as

received.

3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-dimethylpropionic

acid

(Q 3 PA) was prepared according to literature procedures.20 Enzyme assays were performed using
a quartz 96-well plate (Hellma) on a FLUOstar OPTIMA plate reader from BMG LABTECH.
4.2.2

NADH Calibration Curve Preparation
Phosphate-buffered saline (PBS) solutions were prepared by dissolving potassium

phosphate monobasic (4.54 g, 0.033 mol), potassium phosphate dibasic (11.6 g, 0.067 mol), and
potassium chloride (7.45 g, 0.1 M) in one liter of nanopure water/organic solvent. The pH was
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adjusted by adding a concentrated solution of potassium hydroxide dropwise.

Fetal bovine

serum (FBS) was added to give a final concentration of 0.007% w/v. Standard solutions of β nicotinamide adenine dinucleotide reduced disodium salt (NADH) were prepared by diluting
stock NADH solutions in solvent-PBS into the same solvent system.

A calibration curve for

each solvent-PBS system was obtained by placing 200 µL of the NADH standard solutions into
the quartz 96-well plate.

Absorbance measurements were obtained using the λ = 340 nm filter

with each scan containing 40 flashes. Each experiment was done in triplicate.
4.2.3

Enzyme Assay Conditions
NQO1 assays for the reduction of Q 3 PA were performed by following reduction in

absorbance at 340 nm for the conversion of reduced NADH to the oxidized form NAD+. Scans
were taken every 4 seconds for 44 seconds at room temperature (22 to 24 °C) using a FLUOstar
OPTIMA plate reader, and the assays were performed in a quartz 96-well plate (Hellma).
Recombinant human NQO1 (Sigma-Aldrich) in pH 7.4, 0.1 M solvent-PBS and supplemented
with 0.007% bovine serum albumin (BSA) was used. Stock solutions of Q 3 PA were prepared in
the 0.1 M solvent-PBS and diluted in buffer to a final concentration between 25 × 10−6 and 350 ×
10−6 M. Total volume per well was 200 × 10−6 L with a final NQO1 content of 5 × 10−7 g. Assays
were initiated by the instrument-injection of NADH so as to yield a final NADH concentration of
100 × 10−6 M. All assays were performed in triplicate. Rate versus [Q 3 PA] curves were fitted
with a non-linear least-squares algorithm so as to obtain apparent K m and V max values.
4.3

Results and Discussion

4.3.1

NADH Calibration Curves
To determine the kinetic parameters for hNQO1 in each solvent system, the oxidation of

NADH to NAD+ was followed over 44 seconds.
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This is possible because NADH strongly

absorbs at 340 nm and NAD+ does not. To ensure proper conversion from absorbance units to
concentration units for each assay, a calibration curve for NADH was produced for all solventPBS systems, Figure 4.2.
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Figure 4.2. Calibration curves for NADH in 5% DMSO-PBS (A), 10% DMSO-PBS (B), 5%
Ethanol-PBS (C), 10% Ethanol-PBS (D), 5% ACN-PBS (E), and 10% ACN-PBS (F) a quartz
96-well plate. Each solution contained 0.1M PBS supplemented with 0.007% FBS and had a pH
of 7.4. λ = 340 nm.
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While each extinction coefficient was relatively close to that of NADH in pH 7.4, 0.1 M
PBS with 0.007% FBS (4390 M-1 cm-1 )16 , they did vary slightly.

Extinction coefficients (ε ) for

5% and 10% DMSO-PBS were measured to be 3879 ± 170 M-1 cm-1 and 4090 ± 106 M-1 cm-1 ,
respectively.

While ε in 5% and 10% ethanol-PBS systems was 4610 ± 62 M-1 cm-1 and

4120 ± 111 M-1 cm-1 , respectively; in 5% and 10% ACN-PBS, ε was found to be
4020 ± 51 M-1 cm-1 and 4323 ± 20 M-1 cm-1 , respectively. Because all calibration curves were run
in triplicate and produced expected results, the values were considered acceptable and used for
each assay.
4.3.2

Solvent Effect on NQO1 Kinetics
To determine what effect, if any, organic solvents would impact the ability of hNQO1 to

catalyze the reduction of quinones, multiple enzyme assays were performed in a wide variety of
solvent-containing systems with differing percentages of solvent in each system.

To ensure it

was a solvent-dependent experiment, all other parameters except solvent type and percentage
were kept constant. For all systems, the pH was adjusted to 7.4, the substrate used was always
Q 3 PA each system contained 0.007% FBS, every assay contained 0.5 µg enzyme from the same
batch, assays were run in triplicate, NADH concentration was 100 µM, and all systems contained
0.1 M PBS and 0.1 M KCl. The solvents tested were ACN, EtOH, and DMSO at 5% and 10% in
each solvent-PBS system, Figure 4.3.
After each assay was completed, apparent Michaelis-Menten kinetic parameters
were obtained using the computer program from Cleland, Table 4.1.21 This program determines
values and their error from least squares fitting to the equation:

𝑉=

𝑉max × [𝑆]
𝐾m +[𝑆]
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Equation 4.1

where V is the initial velocity of catalysis at a given concentration, [S] is substrate concentration,
V max is theoretical maximum velocity, and K m is the substrate concentration of an estimate for
the equilibrium constant for S binding to an enzyme.

Though there was error between the

individual replicates, the averages for each assay produced quality data for fitting to Equation
Comparison of all V max values showed low calculated error from the least squares fit

4.1.

equation, with 12% error or less.
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Figure 4.3. Michaelis-Menten kinetics plot of hNQO1 (0.5 µg) towards Q 3 PA in different
solvent systems. Solvent systems in PBS are: 5% DMSO (A), 10% DMSO (B), 5% EtOH (C),
10% EtOH (D), 5% ACN (E), 10% ACN (F).
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Figure 4.3 Continued
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Kinetic parameters for the reduction of Q 3 PA by hNQO1 in different solvent-PBS

%
Solvent

K m (µM)

V max (µmol·min-1 ·mg-1
hNQO1

k cat (sec-1 )

k cat /K m (M-1 ·sec-1 )

0

158 ± 41

38 ± 5

19.6 ± 2.6

(1.2 ± 0.4) × 105

5

55 ± 5

12.3 ± 0.3

6.33 ± 0.15

(1.1 ± 0.1) × 105

10

26 ± 3

2.54 ± 0.08

1.31 ± 0.00

(5.8 ± 0.6) × 104

5

180 ± 20

37 ± 2

19.1 ± 1.0

(1.1 ± 0.1) × 105

10

264 ± 54

20.4 ± 2.5

10.5 ± 1.3

(4.0 ± 0.2) × 104

5

94 ± 9

25 ± 1

5.4 ± 0.5

(5.7 ± 0.6) × 104

10

115 ± 8

9.9 ± 0.3

5.1 ± 0.2

(4.4 ± 0.4) × 104

DMSO

EtOH

ACN

When compared to the V max obtained for hNQO1 towards Q 3 PA in buffer only (38

µmol·min-1·mg-1), measurement of the solvent in all cases appears to cause an inhibition of the
enzyme.

It is also seen that increasing the amount of solvent in the assay environment

substantially decreases the V max for hNQO1, Figure 4.5. For all three solvents at 10%, hNQO1 is
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inhibited by 93% in DMSO, 46% in EtOH, and 74% in ACN. As for the 5% systems, hNQO1
has 68%, 3%, and 34% lower V max in DMSO, EtOH, and ACN, respectively. It is clear that
DMSO has the most detrimental effect on hNQO1 catalysis when compared to ACN and EtOH,
and ACN has more of an effect than EtOH. As stated above, more polar solvents can penetrate
into enzymes further creating a more perturbed state. The order of polarity for the three solvents
is: DMSO > ACN > EtOH.22

Also stated above is the fact that solvents with higher dielectric

constants produce more electrostatic interactions causing the enzyme to be more rigid. The order
of increasing dielectric constants is: DMSO (46.7) > ACN (37.5) > EtOH (24.3).14 This order of
polarity and dielectric constants correlates well with the V max values decreasing from EtOH, to
ACN, and then to DMSO.

From this analysis, it is clear that ethanol provides the best organic

solvent when a substrate needs to be dissolved before introduction into an assay. Even at just a
5% solvent amount, DMSO and ACN considerably reduced the ability of hNQO1 to catalyze the
reaction, while hNQO1 remains essentially completely active in ethanol.

The same cannot be

said for assays containing 10% organic solvent, where hNQO1 retains only 54% of its activity or

Vmax (µmol·min-1·mg-1
hNQO1)

less.
40
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Figure 4.4. Comparison of the V max values calculated for hNQO1 towards Q 3 PA in different
solvent-PBS systems.
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Using the molecular weight of 31,000 g/mol for the hNQO1 monomer, catalytic activity
(k cat ) was calculated from the V max values.23

From this, catalytic efficiencies (k cat /K m ) were

calculated for hNQO1 in each solvent-PBS system, Table 4.1. When comparing these values, it
was noticed that hNQO1 was actually least efficient in ACN and was similarly efficient in
DMSO and EtOH. For the 5% solvent systems, ACN was only 46% as efficient as hNQO1 in
only buffer; while EtOH and DMSO were 85% and 93% as efficient, respectively.

But, the

ability of hNQO1 to work properly was significantly reduced to 36%, 32%, and 47% for ACN,
EtOH, and DMSO, respectively, when the assay was performed in 10% solvent-PBS.

This

comparison demonstrates that even though the enzyme loses a majority of its activity in DMSO
at 5%, its efficiency is relatively close to that of an assay with no organic solvent.

This is

possible even though V max is substantially reduced, K m is also reduced by a large amount
indicating a tighter substrate binding to the enzyme.

An increase in organic solvent from 5% to

10% produces an enzyme that maintains less than half of its catalytic efficiency.
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Figure 4.5. Comparison of the k cat /K m values calculated for hNQO1 towards Q 3 PA in different
solvent-PBS systems.
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4.4

Conclusions
Here, it was demonstrated the effect of three different organic solvents (ACN, EtOH, and

DMSO) had on the ability of hNQO1 to catalyze the reduction of Q 3 PA to a hydroquinone.
These three solvents produced results using Michaelis-Menten kinetics that followed previous
trends of more polar solvents penetrating deeper into enzymes causing a more drastic change in
the 3D shape of the enzyme and solvents with higher dielectric constants producing more rigid
enzymes.9

DMSO has been previously used to study the overall and secondary structures of

proteins because it strongly perturbs proteins.24-25 While the two methyls in DMSO are thought
to interact with the hydrophobic residues in proteins, the strong proton-accepting nature of the
sulfoxide is thought to be the driving force behind the ability of DMSO to strongly denature
proteins.25

This strong affinity for protons leads to the disruption of hydrogen-bonding and

weakening the hydrophobic interactions throughout the protein and its secondary structures,
leading to a more unfolded state as the concentration of DMSO is increased.24,

26

Alcohols have

also been used to study the structures of proteins because they have not only been found to
denature proteins in some cases, but also stabilized helixes, β-sheet hairpins, and other secondary
structures.27-29

This stabilization effect can be partially explained by the decrease in polarity in

the ethanol-water solvent system where ethanol preferentially associates with protein surface
hydrophobic sites, which weakens the hydrophobic interactions and strengthens the hydrogenbonds in helixes and other secondary structures.27-28

Though ethanol is a proton donor, it has

been shown to bind to hydrogen donors (amides) and hydrogen acceptors (carbonyls) equally.27
Though enzyme properties in the presence of DMSO vary from enzyme-to-enzyme, with some
being activated and other having negligible catalytic differences30 , NQO1 is greatly inhibited
when in the presence of DMSO.

From the results above, it was found that DMSO and ACN
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drastically reduced the enzymes V max by 68% and 34%, respectively, at only a 5% solvent level.
On the other hand, hNQO1 retained all of its activity in 5% EtOH.

But, the shift from 5%

solvent to 10% solvent created a poorly catalyzing hNQO1 which had 54% of its activity in
EtOH, 7% in DMSO, and 26% in ACN. With the sharp reduction of V max in DMSO, hNQO1
retains a majority of its efficiency at 5% DMSO.

This was due to the concurrent reduction in

K m , which demonstrates tighter binding substrates along with slower turnover.

From the three

solvents tested, EtOH is superior to ACN and DMSO at 5% levels, allowing the enzyme to retain
97% of its V max and remain 87% efficient. Though DMSO is most commonly used to dissolve
substrates for assays, ethanol is now shown to be the better option to obtain kinetic values which
should more closely resemble those obtained in 100% buffer.
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CHAPTER 5
CONCLUSIONS AND OUTLOOK
5.1

Summary
The overall goal of this research was the development and implementation of an

activatable latent fluorophore for intracellular NQO1 detection.

The fluorescent probe was

designed to be sensitive by having a nearly non-fluorescent quenched state and a highly
fluorescent free dye.

The probe’s receptor unit needed to be highly selective for NQO1 2-

electron reduction catalysis and undergo rapid lactonization from the probe to reveal the dye’s
fluorescent signal.

The probe was analyzed by determining the quantum yield of each free dye

and capped dye, determining enzyme kinetic parameters, imaging the probe in different cell lines
using fluorescence microscopy, and determining the ability to differentiate between hNQO1positive and hNQO1-negative cell lines using flow cytometry.
Quantum yield values for rhodamine110-based latent fluorophores in pH 7.4, 0.1 M PBS
yielded 0.005 for Q 3 -Rho-Morph and 0.48 for Rho-Morph, which leads to a 96-fold increase in
fluorescence.

Rho-Morph excitation and emission maxima were measured to be λ ex = 490 nm

and λ em = 520 nm. Q 3 -Rho-Morph was found to be rapidly activated with the release of RhoMorph by sodium dithionite and was highly stable in the presence of high concentrations of
glutathione, ascorbic acid, and dithiothreitol.

Along with sodium dithionite, it was observed that

Q 3 -Rho-Morph was activated by NQO1 in the presence of NADH and was very stable while in a
solution of NADH only. The kinetic parameters were measured to be 0.00214 ± 0.00013 µmol
min-1 mg·NQO1-1 for V max and 46.4 ± 7.4 M-1 sec-1 for k cat /K m . The low catalytic efficiency for
NQO1 towards Q 3 -Rho-Morph is most likely due to the steric hindrance of the rhodamine
species in close proximity to the quinone substrate, thus preventing the probe from effectively
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entering the active site.

Using fluorescence and absorbance spectroscopy, it was found that the

Rho-Morph species was readily reduced by a low concentration in NADH in a pH 7.4, 0.1 M
PBS solution. The reduction led to a rapid loss of absorbance at λ = 485 nm and, coincidentally,
a loss of fluorescence.

This catalytic inefficiency and reduction by NADH led to the inability to

image the probe intracellularly in two NQO1-positive cell lines (HT-29 and A549).

Images

obtained for the positive cell lines looked very similar to the negative cell line (H596), where all
three contained a faint fluorescent intracellular signal.

This signal most likely derived from the

background of the capped probe. It has also been reported that a Rho-Morph analogue switches
to a cell permeant lactone form in polar media, which can also lead to a loss of intracellular
signal.1

This inability to image the probe was found to occur even after adjusting the probe

concentration and a wide range of incubation times.
Q 3 NN was designed to attach the quinone to the fluorophore via a short ethylene spacer
as to minimize the steric hindrance and allow the probe to freely enter the enzyme active site,
which in turn should increase the V max and catalytic efficiency.

The fluorophore used was a

naphthalimide-butyl species that has a large Stokes shift of 116 nm and was measured to excite
at 374 nm and emit at 490 nm.

Quantum yields for Q 3 NN and NN were calculated at 0.23 and

0.007, with a 33-fold fluorescence enhancement.

Where Q 3 -Rho-Morph was quenched by a

structural change of the Rho-Morph species, Q 3 NN possessed a much different quenching
mechanism.

It used a photoinduced electron transfer (PeT) process, prior to and post-reduction

of the quinone, to prevent the excited electron in the fluorophore from relaxing and emitting a
photon.

To determine if this PeT process between the naphthalimide dye and the quinone was

possible, the PeT free energy change was calculated using the Rehm-Weller equation.

To

accomplish this, the oxidation and reduction potentials were measured for NN and the trimethyl-
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quinone acid. ∆G PeT for the oxidative electron transfer prior to quinone reduction was calculated
to be -0.35. Post-reduction was calculated at -2.69 for the reductive electron transfer. Both are
sufficiently negative to give nearly complete quenching of the fluorophore.
quinone is removed by lactonization is the fluorophore’s signal revealed.

Only after the

Similar to Q 3 -Rho-

Morph, Q 3 NN was rapidly activated in the presence of sodium dithionite. As a control to ensure
PeT is the quenching mechanism after hydroquinone formation, a second probe (Q 1 NN) was
synthesized that contained a similar quinone without the trimethyl-lock.

This probe was also

mixed with sodium dithionite, of which the fluorescence signal was revealed at a much slower
rate.

By conjugating the quinone to a short linker, the enzymatic efficiency was raised when

compared to Q 3 -Rho-Morph, where V max = 0.037 ± 0.002 µmol min-1 mg·NQO1-1 and k cat /K m =
4.9 (± 1.0) x 103 M-1 sec-1 . And of high importance, NADH caused a minimal decrease in the
fluorescence signal of NN in pH 7.4, 0.1 M PBS.

To determine if it was possible to visually

observe the difference between cell lines with and without NQO1, HT-29, A549, and H596 cells
were incubated with 20 µΜ Q 3 NN for 10 minutes. These cells were then observed under a 365
nm lamp, where HT-29 and A549 were easily distinguishable from H596. The NQO1-positive
cells emitted a blue light and H596 cells were colorless. The same cell lines were also analyzed
using flow cytometry and widefield imaging.

In both cases, the two NQO1-positive cell lines

were easily differentiated from H596 with a very short incubation period of 10 minutes.
Fluorescence imaging was also performed using two-photon confocal microscopy.

The three

cell lines used previously were used again, along with a second negative cell line (H446).

As

before, the negative and positive cell lines were differentiated with only a 10 minute incubation
period.

It was calculated that the average cytosolic fluorescence signal was 13-fold higher in

A549 compared to H596 and 3.66 x 104 -fold higher than H446 cells.
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Similar results were

obtained with the HT-29 cell line, with the cytosolic intensity being 15-fold higher compared to
H596 and a 4.51 x 104 increase compared to H446. The released dye, NN, was colocalized with
a lysotracker dye in the HT-29 cells and it was determined that the free dye preferentially
accumulated in acidic compartments.

Important to future applications of the probe for in vivo

analysis is the effect it has on cell health.

After one hour, cell viability for HT-29, A549, and

H596 was 97.7%, 98.8%, and 100%, respectively, and 97.7%, 98.7%, and 98.4%, respectively,
after one day.
To develop better enzyme assay conditions that should be more reliable and consistent
between compound testing, solvent effects were determined on the ability of NQO1 to catalyze
the reduction of a simple quinone trimethyl-lock system.

One effect that is rarely taken into

account is the solvent in which the substrate is dissolved.

These solvents can perturb the

enzyme’s 3D structure by altering the hydrogen bonding of water to the protein or by changing
the polarity of the medium.

To determine how different solvents can affect the ability of NQO1

to catalyze a reaction, acetonitrile (ACN), ethanol (EtOH), and dimethyl sulfoxide (DMSO) were
used in assays at 5% or 10%. While each solvent percentage was changing, the buffer (0.1 M
PBS), salt (0.1 M potassium chloride), and pH 7.4 stayed constant. The results revealed that the
high polar solvents (DMSO) negatively affected NQO1 more than the less polar solvents (ACN
and EtOH). This trend was reasonable because higher polar solvents have the ability to penetrate
deeper into the enzyme structure.

This further penetration would create a larger shift in the 3D

structure of the enzyme, specifically the active site.

It was found that DMSO and ACN

drastically reduced the enzyme’s V max by 68% and 34% when compared to an assay with no
solvent, respectively, and NQO1 retained all of its activity in 5% EtOH. However, the shift from
5% solvent to 10% solvent was more detrimental to hNQO1 and had 54% of its activity in
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ethanol, 7% in DMSO, and 26% in ACN.

Catalytic efficiencies (k cat /K m ) were calculated for

each solvent-PBS system and compared to each other. For the 5% solvent systems, NQO1 in
ACN was only 46% as efficient as compared to 100% buffer, while EtOH and DMSO were 85%
and 93% as efficient, respectively. The k cat /K m was significantly reduced to 36%, 32%, and 47%
for ACN, EtOH, and DMSO, respectively, when the assay was performed in 10% solvent-PBS.
From the solvents tested, it was apparent that NQO1 assays containing 5% EtOH would be
preferable for future assays since NQO1 retained all of its activity.

Though DMSO is more

commonly used in vitro, due to its minimal effect on cells, it is not as suitable for enzymatic
assays involving NQO1.
5.2

Conclusions
The results demonstrated in this research outline the development and use of off-on latent

fluorophores for the detection of hNQO1.

Though the rhodadamine110-based probe was

unsuccessfully used in vitro, it was found to be activated by hNQO1 in a timely manner and was
stable towards biological reductants such as glutathione, ascorbic acid, and even dithiothreitol.
The probe’s main failures for in vitro imaging were associated with the fluorescent dye itself.
Though the rhodamine-morpholino urea species was highly fluorescent, it was also susceptible to
reduction by low concentrations of NADH.

Along with the loss of fluorescence from reduction,

it has been previously reported by a different research group that it forms a membrane permeant
lactone form.1

These two factors appeared to be detrimental in the ability of the probe to be

fluorescently imaged in cell lines with hNQO1 activity.
A second probe was synthesized in which the quinone receptor group was attached to a
short ethylene linker and attached to a naphthalimide dye. This probe exhibited a unique off-on
type activation in that the quinone acted as an electron acceptor in a photoinduced electron
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transfer quenching mechanism.

By studying a negative control type dye that did not contain the

trimethyl-lock and by using cyclic voltammetry to determine oxidation/reduction potentials in
order to calculate the free energy change uing the Rehm-Weller equation, it was determined that
the naphthalimide-based probe actually underwent a two-stage quenching mechanism.

The first

stage was prior to reduction, in which the quinone acts as the electron acceptor for the excited
dye and caused a quenching effect.

The second state was post-reduction, where the

hydroquinone acted as an electron donor to the excited fluorophore, also causing quenching until
cyclization and lactone release.

This probe was found be a better NQO1 substrate substantially

better than the rhodamine110-based probed.

This would be most likely due to the bulky

rhodamine-110 group attached directly to the quinone, rather than a much smaller ethylene
linker.

The naphthalimide probe was also found to be effective in tumor cell differentiation

between cells known to contain NQO1 activity and cells with no enzyme activity.

This was

proved by performing widefield fluorescence imaging, confocal and multiphoton microscopy,
and flow cytometry.

Most importantly, the probe was rapidly activated in the NQO1-positive

cells (<10 minutes) and did not show to be cytotoxic to any of the cell lines studied. It was also
demonstrated that the type and percentage of solvent used in the NQO1 enzyme assay can be
detrimental to the enzyme activity.

Here, it was found that DMSO at only 5% reduced the

enzyme activity by 68%, while EtOH and ACN only reduced the activity by 3% and 34%,
respectively.
5.3

Outlook
With fluorescence-based optical imaging for the diagnosis and treatment of diseases still

in its infancy, there is much work left to be accomplished to have a greater impact in the clinic.
This development of fluorescent probes has the potential to aid in the design of drugs by
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obtaining pharmacokinetic and biodistribution information, along with aiding in fields such as
diagnosis and real-time surgical guidance.

The goal of all fluorogenic probes for disease

detection and analysis is to have high selectivity and sensitivity. This is attainable by obtaining a
better understanding of the macro- and microenvironments of the tissue being studied, and
utilizing the unique features that differentiates them from healthy tissues.
With the amount of previously reported information on the design and implementation of
drug molecules that are selectively activated by NQO1, it is rather surprising NQO1 has not been
used in the detection and treatment of cancer using biomedical imaging.

Information in this

dissertation provides an excellent starting point towards the design of next generation NQO1activatable fluorophores.

The probe structure contains two moieties, quinone and fluorophore,

that can readily be changed to increase the substrate efficiency and allow adjustment of the
optical properties to obtain a more biologically useable fluorophore.

These properties can be

adjusted while maintaining the selectivity for activation and still maintain a high signal-tobackground ratio.

The naphthalimide probe possesses the capability to conjugate the probe to

different entities, such as other fluorophores and nanomaterials.

By attaching fluorophores

which emit in the red, there is the ability to create a pseudo-dual color probe using Förster
resonance energy transfer (FRET) and giving the user more quantitative information.

This could

be accomplished by observing the red-emitting fluorescence and the change in fluorescence
through FRET by exciting the naphthalimide probe as it is activated. These probes can also be
attached to biomaterials, such as dextrans, to determine if there is any NQO1 activity in
endosomes or lysosomes.

One could easily attach lipids to the naphthalimide probe to create a

probe-capped liposome system to observe the kinetics of activation and release of the vesicle’s
contents.

More recently, reports have been published about the development of multimodal
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probes that contain an optical imaging motif and a nuclear or magnetic resonance imaging
motif.2,3

This combination of incorporating a biomedical imaging technique commonly used

clinically with an optical imaging agent allows for the development of a two function probe.
One can be used to locate disease sites prior to surgery and a second can give real-time
information during intraoperative procedures.

Whether it’s creating a second generation probe

system or utilizing the probes presented here for in vivo analysis, there is still a large amount of
research left to be performed to develop an NQO1-selective fluorophore which is capable for
clinical applications.
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